<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0404233473
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Papillio
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PALBOCICLIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        125
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        11361.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Arab Pharmaceutical Manufacturing PSC (Sahab) Co Ltd " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Arab Pharmaceutical Manufacturing PSC (Sahab) Co Ltd 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XE33
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Papillio is an anticancer medicine containing the active substance palbociclib.</p><p>&nbsp;</p><p>Palbociclib works by blocking proteins called cyclin-dependent kinase 4 and 6, which regulate cell growth and division. Blocking these proteins can slow down growth of cancer cells and delay the progression of your cancer.</p><p>Papillio is used to treat patients with certain types of breast cancer (hormone receptor-positive, human epidermal growth factor receptor 2-negative) which have spread beyond the original tumour and/or to other organs. It is given together with aromatase inhibitors or fulvestrant, which are used as hormonal anticancer therapies.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Papillio</strong></p><ul><li>If you are allergic to palbociclib or any of the other ingredients of this medicine (listed in section 6).</li><li>Use of preparations containing St. John&rsquo;s Wort should be avoided while you are taking Papillio.</li></ul><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before taking Papillio.</p><p>&nbsp;</p><p>Papillio may reduce the number of your white blood cells and weaken your immune system. Therefore, you may be at greater risk of getting an infection while you are taking Papillio.</p><p>&nbsp;</p><p>Tell your doctor, pharmacist or nurse if you experience signs or symptoms of an infection, such as chills or fever.</p><p>&nbsp;</p><p>You will have regular blood tests during treatment to check whether Papillio affects your blood cells (white blood cells, red blood cells, and platelets).</p><p>&nbsp;</p><p>Papillio may cause severe or life-threatening inflammation of the lungs during treatment that can lead to death. Tell your healthcare provider right away if you have any new or worsening symptoms including:</p><ul><li>Difficulty breathing or shortness of breath</li><li>Dry cough</li><li>Chest pain</li></ul><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Palbociclib is not to be used in children or adolescents (under 18 years of age).</p><p>&nbsp;</p><p><strong>Other medicines and Papillio</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Papillio may affect the way some other medicines work.</p><p>&nbsp;</p><p>In particular, the following may increase the risk of side effects with Papillio:</p><ul><li>Lopinavir, indinavir, nelfinavir, ritonavir, telaprevir, and saquinavir used to treat HIV infection/AIDS.</li><li>Clarithromycin and telithromycin antibiotics used to treat bacterial infections.</li><li>Voriconazole, itraconazole, ketoconazole, and posaconazole used to treat fungal infections.</li><li>Nefazodone used to treat depression.</li></ul><p>&nbsp;</p><p>The following medicines may have increased risk of side effects when given with Papillio:</p><ul><li>&nbsp;Quinidine generally used to treat heart rhythm problems.</li><li>Colchicine used to treat gout.</li><li>Pravastatin and rosuvastatin used to treat high cholesterol levels.</li><li>Sulfasalazine used to treat rheumatoid arthritis.</li><li>Alfentanil used for anaesthesia in surgery; fentanyl used in pre-procedures as a pain reliever as well as an anaesthetic.</li><li>Cyclosporine, everolimus, tacrolimus, and sirolimus used in organ transplantation to prevent rejection.</li><li>Dihydroergotamine and ergotamine used to treat migraine.</li><li>Pimozide used to treat schizophrenia and chronic psychosis.</li></ul><p>&nbsp;</p><p>The following medicines may reduce the effectiveness of Papillio:</p><ul><li>Carbamazepine and phenytoin, used to stop seizures or fits.</li><li>Enzalutamide to treat prostate cancer.</li><li>Rifampin used to treat tuberculosis (TB).</li><li>St. John&rsquo;s Wort, an herbal product used to treat mild depression and anxiety.</li></ul><p>&nbsp;</p><p><strong>Papillio with food and drink</strong></p><p>Avoid grapefruit and grapefruit juice while you are taking Papillio as it may increase the side effects of Papillio.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>You should not use Papillio if you are pregnant.</p><p>&nbsp;</p><p>You should avoid becoming pregnant while taking Papillio.</p><p>&nbsp;</p><p>Discuss contraception with your doctor if there is any possibility that you or your partner may become pregnant.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Women of childbearing potential who are receiving this medicinal product, or their male partners should use adequate contraceptive methods (e.g., double-barrier contraception such as condom and diaphragm). These methods should be used during therapy and for at least 3 weeks after completing therapy for females and for at least 14 weeks for males.</p><p>&nbsp;</p><p><em>Breast-feeding </em></p><p>You should not breast-feed while taking Papillio. It is not known if Papillio is excreted in breast milk.</p><p>&nbsp;</p><p><em>Fertility </em></p><p>Palbociclib may decrease fertility in men.</p><p>&nbsp;</p><p>Therefore, men may consider sperm preservation before taking Papillio.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Tiredness is a very common side effect. If you feel unusually tired, take special care when driving or using machines<strong>.</strong></p><p>&nbsp;</p><p><strong>Papillio </strong><strong>contains lactose and sodium</strong></p><p>Papillio contains lactose (found in milk or dairy products). Each 75 mg, 100 mg and 125 mg hard capsule contains 55.8 mg, 74.4 mg or 93 mg lactose; respectively. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p><strong>&nbsp;</strong></p><p>Papillio contains sodium. Papillio contains less than 1 mmol sodium (23 mg) per hard capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>The recommended dose is 125 mg of Papillio taken once a day for 3 weeks followed by 1 week without taking Papillio. Your doctor will tell you how many capsules of Papillio to take.</p><p>&nbsp;</p><p>If you experience certain side effects while you are taking Papillio (see section 4 &ldquo;Possible side effects&rdquo;), your doctor may lower your dose or stop treatment, either temporarily or permanently. The dose may be lowered to one of the other available strengths 100 mg or 75 mg.</p><p>&nbsp;</p><p>Take Papillio once a day at about the same time every day with food, preferably a meal.</p><p>&nbsp;</p><p>Swallow the capsule whole with a glass of water. Do not chew or crush the capsules. Do not open the capsules.</p><p>&nbsp;</p><p><strong>If you take more </strong><strong>Papillio </strong><strong>than you should</strong></p><p>If you have taken too much Papillio, see a doctor or go to a hospital immediately. Urgent treatment may be necessary.</p><p>&nbsp;</p><p>Take the carton and this leaflet, so that the doctor knows what you have been taking.</p><p>&nbsp;</p><p><strong>If you forget to take </strong><strong>Papillio</strong></p><p>If you miss a dose or vomit, take your next dose as scheduled. Do not take a double dose to make up for the forgotten capsules.</p><p>&nbsp;</p><p><strong>If you stop taking </strong><strong>Papillio</strong></p><p>Do not stop taking Papillio unless your doctor tells you to.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them:</p><p>&nbsp;</p><p><strong><em>Contact your doctor immediately if you have any of these symptoms:</em></strong></p><ul><li>Fever, chills, weakness, shortness of breath, bleeding, or easy bruising which could be a sign of a serious blood disorder.</li><li>Difficulty breathing, dry cough or chest pain which could be a sign of inflammation of the lungs.</li></ul><p>&nbsp;</p><p><strong><em>Other side effects with palbociclib may include: </em></strong></p><p><strong>Very common side effects (may affect more than 1 in 10 people): </strong></p><ul><li>Infections</li><li>Reduction in white blood cells, red blood cells, and blood platelets</li><li>Feeling of tiredness</li><li>Decreased appetite</li><li>Inflammation of the mouth and lips (stomatitis), nausea, vomiting, diarrhoea</li><li>Rash</li><li>Hair loss</li><li>Weakness</li><li>Fever</li><li>Abnormalities in liver blood tests</li><li>Dry skin</li></ul><p>&nbsp;</p><p><strong>Common side effects (may affect up to 1 in 10 people): </strong></p><ul><li>Fever with a drop in the white blood cell count (febrile neutropenia)</li><li>Blurred vision, increased tearing, dry eye</li><li>Alteration in taste (dysgeusia)</li><li>Nosebleed</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 30&deg;C.</p><p>Store in the original package.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice that the pack is damaged or shows signs of tampering.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is palbociclib.</p><p>&nbsp;</p><p>Each hard capsule of Papillio 75 mg Hard Capsules contains 75 mg palbociclib.</p><p>&nbsp;</p><p>Each hard capsule of Papillio 100 mg Hard Capsules contains 100 mg palbociclib.</p><p>&nbsp;</p><p>Each hard capsule of Papillio 125 mg Hard Capsules contains 125 mg palbociclib.</p><p>&nbsp;</p><p>The other ingredients are microcrystalline cellulose, lactose, sodium starch glycolate, aerosil and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Papillio 75 mg Hard Capsules are polished hard capsules containing yellow to orange crystalline powder with opaque caramel body/opaque caramel cap imprinted in black with “SP03” logo on both body and cap in aluminum/aluminum blisters.

Papillio 100 mg Hard Capsules are polished hard capsules containing yellow to orange crystalline powder with opaque caramel body/opaque caramel cap imprinted in black with “SP02” logo on both body and cap in aluminum/aluminum blisters.

Papillio 125 mg Hard Capsules are polished hard capsules containing yellow to orange crystalline powder with caramel body/caramel cap imprinted in black with “SP01” logo on both body and cap in aluminum/aluminum blisters.

Pack size: 21 hard capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: jpimedical@hikma.com</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>The Arab Pharmaceutical Manufacturing PSC</p><p>Sahab</p><p>Industrial City</p><p>P.O. Box 41&nbsp;</p><p>Amman 11512, Jordan</p><p>Tel: + (962-6) 4023916</p><p>Fax: + (962-6) 4023917</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>&nbsp; &nbsp; Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>&nbsp; &nbsp; Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 09/2020; version number SA1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">بابيليو هو دواء مضاد للسرطان يحتوي على المادة الفعّالة بالبوسيكليب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعمل بالبوسيكليب من خلال إحصار بروتينات تسمى الكيناز المعتمد على السايكلين ٤ و٦ التي تنظّم نمو الخلايا وانقسامها. قد يؤدي إحصار هذه البروتينات إلى إبطاء نمو الخلايا السرطانية وتأخير تطور السرطان لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم بابيليو لعلاج المرضى المصابين بأنواع معينة من سرطان الثدي (مستقبل الهرمون-الإيجابي، مستقبل عامل نمو الجلد البشري ٢- السلبي) الذي انتشر خارج الورم الأصلي و/أو إلى الأعضاء الأخرى. يعطى مع مثبطات الأروماتاز أو دواء فولفيسترانت، التي تستخدم باعتبارها علاجات هرمونية مضادة للسرطان.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول بابيليو</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لبالبوسيكليب أو أي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم ٦).</li><li>يجب تجنب استخدام المستحضرات التي تحتوي على نبتة سانت جون أثناء تناول بابيليو.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدث مع طبيبك، الصيدلي، أو الممرض قبل استخدام بابيليو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يُقلّل بابيليو من عدد خلايا الدم البيضاء لديك ويُضعف جهازك المناعي. لذلك، قد تزداد خطورة تعرضك للإصابة بعدوى أثناء تناول بابيليو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرض إذا كنت تعاني من علامات أو أعراض عدوى، مثل القشعريرة أو الحمّى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ستجري اختبارات دم دورية أثناء العلاج للتحقق مما إذا كان بابيليو يؤثر على خلايا دمك (خلايا الدم البيضاء وخلايا الدم الحمراء والصفائح الدموية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتسبب بابيليو في حدوث التهاب رئوي شديد أو مهدّد للحياة أثناء العلاج يمكن أن يؤدي إلى الوفاة. أخبر مقدم الرعاية الصحية على الفور إذا ظهرت عليك أي أعراض جديدة أو متفاقمة من بينها:</p><ul dir="rtl"><li>صعوبة أو ضيق في التنفس</li><li>سعال جاف</li><li>ألم في الصدر</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يستخدم بالبوسيكليب لدى الأطفال أو المراهقين (دون ١٨ عاماً).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وبابيليو</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تأخذ، أخذت مؤخراً، أو قد تأخذ أية أدوية أخرى. قد يؤثر بابيليو على طريقة عمل بعض الأدوية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تتسبب الأدوية التالية، على وجه الخصوص، في زيادة خطر الإصابة بالآثار الجانبية مع استخدام بابيليو:</p><ul dir="rtl"><li>أدوية لوبينافير وإندينافير ونيلفينافير وريتونافير وتيلابريفير وساكوينافير المستخدمة في علاج فيروس نقص المناعة البشري/الإيدز.</li><li>المضادات الحيوية كلاريثرومايسين وتيليثرومايسين المستخدمة في علاج حالات العدوى البكتيرية.</li><li>أدوية فوريكونازول وإتراكونازول وكيتوكونازول وبوساكونازول المستخدمة في علاج حالات العدوى الفطرية.</li><li>نيفازودون المستخدم في علاج الاكتئاب.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">قد تزيد الأدوية التالية من خطورة الآثار الجانبية عند إعطائها مع بابيليو:</p><ul dir="rtl"><li>كينيدين المستخدم بشكل عام في علاج مشاكل نظم القلب.</li><li>كولشيسين المستخدم في علاج النقرس.</li><li>برافاستاتين ورسيوفاستاتين المستخدمان في علاج ارتفاع مستويات الكوليسترول.</li><li>سلفاسالازين المستخدم في علاج التهاب المفاصل الروماتويدي.</li><li>ألفنتانيل المستخدم للتخدير في الجراحة وفنتانيل المستخدم في الإجراءات السابقة للجراحة باعتباره مسكناً للألم وكذلك مخدراً.</li><li>أدوية سيكلوسبورين وإيفيروليموس وتاكروليمس وسيروليموس المستخدمة في زراعة الأعضاء لمنع رفض العضو.</li><li>ثنائي هيدروأرغوتامين وأرغوتامين المستخدمان في علاج الصداع النصفي.</li><li>بيموزيد المستخدم في علاج انفصام الشخصية والذهان المزمن.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">قد تقلل الأدوية التالية من فاعلية بابيليو:</p><ul dir="rtl"><li>كاربامازيبين وفينيتوين المستخدمان في إيقاف التشنجات أو نوبات الصرع.</li><li>إنزالوتاميد المستخدم في علاج سرطان البروستاتا.</li><li>ريفامبيسين المستخدم في علاج السل.</li><li>نبتة سانت جون، مستحضر عشبي يستخدم في علاج القلق والاكتئاب الخفيف.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بابيليو مع الطعام والشراب</strong></p><p dir="RTL">تجنب تناول الجريب فروت وعصيره أثناء تناول بابيليو لأن ذلك قد يؤدي إلى زيادة الآثار الجانبية لبابيليو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل، الرضاعة والخصوبة</strong></p><p dir="RTL">ينبغي عدم استخدام بابيليو إذا كنتِ حاملاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عليك تجنب الحمل أثناء تناول بابيليو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ناقش وسائل منع الحمل مع طبيبك إذا كانت هناك احتمالية حدوث حمل لكِ/لشريكتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى استشارة طبيبك أو الصيدلي إذا كنت حاملاً أو مرضع، أو تعتقدين بأنك حاملاً أو تخططين لذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب على النساء المحتمل حملهنّ اللاتي يتناولن هذا المستحضر الطبي أو شركائهن الذكور استخدام وسائل مناسبة لمنع الحمل (أي، منع الحمل باستخدام عازل ثنائي مثل الواقي الذكري والواقي الأنثوي). يجب استخدام هذه الوسائل أثناء العلاج ولمدة لا تقل عن ٣ أسابيع بعد اكتمال العلاج للإناث ومدة لا تقل عن ١٤ أسبوعاً للذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الرضاعة الطبيعية</em> <em>&nbsp;</em></p><p dir="RTL">يجب ألا ترضعي رضاعة طبيعية أثناء تناول بابيليو. ليس من المعروف إذا ما كان بابيليو يتسرب إلى حليب الأم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الخصوبة</em> <em>&nbsp;</em></p><p dir="RTL">قد يقلل بالبوسيكليب الخصوبة لدى الرجال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لذلك، قد يراعي الرجال حفظ الحيوانات المنوية قبل تناول بابيليو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير </strong><strong>بابيليو</strong><strong> على القيادة واستخدام الآلات </strong></p><p dir="RTL">يعتبر التعب أحد الآثار الجانبية الشائعة جداً. إذا كنت تشعر بالتعب غير المعتاد، فعليك توخي الحذر عند القيادة أو استخدام الآلات<strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي بابيليو على اللاكتوز والصوديوم</strong></p><p dir="RTL">يحتوي بابيليو على اللاكتوز (الموجود في الحليب أو منتجات الألبان). تحتوي كل كبسولة صلبة من ٧٥ ملغم، ١٠٠ ملغم و١٢٥ ملغم على ٥٥,٨&nbsp;ملغم، ٧٤,٤ ملغم أو ٩٣ ملغم من اللاكتوز؛ على التوالي. إذا كان طبيبك قد أخبرك بأنك تعاني من حساسية شديدة تجاه بعض السكريات، فاستشره قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي بابيليو على الصوديوم. يحتوي بابيليو على أقل من ١ مليمول صوديوم (٢٣ ملغم) لكل كبسولة صلبة، بمعنى أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائماً كما أخبرك طبيبك أو الصيدلي تماماً. تأكد من طبيبك أو الصيدلي إذا كانت لديك أية استفسارات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها هي ١٢٥ ملغم من بابيليو تؤخذ مرة واحدة يومياً لمدة ٣ أسابيع يليها أسبوع بدون أخذ بابيليو. سيخبرك طبيبك بعدد كبسولات بابيليو التي يجب تناولها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا عانيت من آثار جانبية معينة أثناء تناول بابيليو (انظر القسم ٤ &quot;الآثار الجانبية المحتملة&quot;)، فقد يخفض طبيبك جرعتك أو يوقف العلاج، إما مؤقتاً أو دائماً. قد يتم خفض الجرعة إلى أحد التركيزين الآخرين المتوفرين وهما ١٠٠ ملغم أو ٧٥ ملغم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول بابيليو مرة واحدة يومياً في التوقيت ذاته تقريباً كل يوم مع الطعام، يُفضل مع وجبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ابتلع كبسولة كاملة مع كوب من الماء. لا تمضغ الكبسولات أو تطحنها. لا تفتح الكبسولات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت جرعة زائدة من </strong><strong>بابيليو</strong></p><p dir="RTL">إذا تناولت جرعة زائدة من بابيليو، استشر طبيباً أو توجه إلى مستشفى على الفور. قد يكون من الضروري الخضوع لعلاج طارئ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أحضر العلبة الكرتونية وهذه النشرة معك، حتى يعلم الطبيب ما الدواء الذي تناولته.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول </strong><strong>بابيليو</strong></p><p dir="RTL">إذا نسيت جرعة أو تقيأت، تناول جرعتك التالية حسبما هو محدد. لا تتناول جرعة مضاعفة لتعويض الكبسولات المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول </strong><strong>بابيليو</strong></p><p dir="RTL">لا تتوقف عن تناول بابيليو إلا إذا أخبرك الطبيب بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، يرجى استشارة الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>اتصل بالطبيب على الفور إذا ظهرت عليك أي من هذه الأعراض:</em></strong></p><ul dir="rtl"><li>حمّى أو قشعريرة أو ضعف أو ضيق في التنفس أو نزف أو سهولة التعرض للكدمات حيث قد يكون ذلك إحدى علامات اضطراب خطير في الدم.</li><li>صعوبة في التنفس أو سعال جاف أو ألم بالصدر، حيث قد يكون ذلك إحدى علامات الالتهاب الرئوي.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>قد تشمل الآثار الجانبية الأخرى لبالبوسيكليب: </em></strong></p><p dir="RTL"><strong>آثار جانبية شائعة جداً (قد تؤثر على أكثر من شخص واحد من كل 10 أشخاص): </strong></p><ul dir="rtl"><li>العدوى</li><li>انخفاض في خلايا الدم البيضاء وخلايا الدم الحمراء والصفائح الدموية</li><li>شعور بالتعب</li><li>قلة الشهية</li><li>التهاب الفم والشفتين (التهاب الفم) أو غثيان أو تقيؤ أو إسهال</li><li>طفح جلدي</li><li>تساقط الشعر</li><li>ضعف</li><li>حمّى</li><li>اضطرابات في اختبارات الدم بالكبد</li><li>جفاف الجلد</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص): </strong></p><ul dir="rtl"><li>حمّى يصحبها انخفاض في عدد خلايا الدم البيضاء (قلة العدلات الحموية)</li><li>تشوش الرؤية وزيادة سيلان الدموع وجفاف العين</li><li>تغير في حاسة التذوق (خلل الذوق)</li><li>رعاف</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا يحفظ عند درجة حرارة أعلى من ٣٠&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد&rdquo;EXP&rdquo; . يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أن العبوة تالفة أو تظهر عليها علامات العبث.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. اتبع هذه الإجراءات للحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعّالة هي بالبوسيكليب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل كبسولة صلبة من بابيليو ٧٥ ملغم كبسولات صلبة على ٧٥ ملغم بالبوسيكليب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل كبسولة صلبة من بابيليو ١٠٠ ملغم كبسولات صلبة على ١٠٠ ملغم بالبوسيكليب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل كبسولة صلبة من بابيليو ١٢٥ ملغم كبسولات صلبة على ١٢٥ ملغم بالبوسيكليب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي سيلليلوز بلوري مكروي، لاكتوز، جلايكولات نشا الصوديوم، أيروسيل وستيرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">بابيليو ٧٥ ملغم كبسولات صلبة هي عبارة عن كبسولات صلبة مصقولة تحتوي على مسحوق بلوري لونه أصفر إلى برتقالي ذات جسم غير شفاف بلون الكراميل/غطاء غير شفاف بلون الكراميل مطبوع عليها باللون الأسود شعار &quot;SP03&quot; على جسم الكبسولة والغطاء معاً في أشرطة من الألومينيوم/الألومينيوم.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">بابيليو ١٠٠ ملغم كبسولات صلبة هي عبارة عن كبسولات صلبة مصقولة تحتوي على مسحوق بلوري لونه أصفر إلى برتقالي ذات جسم غير شفاف بلون الكراميل/غطاء غير شفاف بلون الكراميل مطبوع عليها باللون الأسود شعار &quot;SP02&quot; على جسم الكبسولة والغطاء معاً في أشرطة من الألومينيوم/الألومينيوم.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">بابيليو ١٢٥ ملغم كبسولات صلبة هي عبارة عن كبسولات صلبة مصقولة تحتوي على مسحوق بلوري لونه أصفر إلى برتقالي ذات جسم بلون الكراميل/غطاء بلون الكراميل مطبوع عليها باللون الأسود شعار &quot;SP01&quot; على جسم الكبسولة والغطاء معاً في أشرطة من الألومينيوم/الألومينيوم.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">حجم العبوة: ٢١ كبسولة صلبة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد ١٠٦٢٢٩<br />الرياض ١١٦٦٦، المملكة العربية السعودية</p><p dir="RTL">هاتف: ٨١٠٧٠٢٣ (١١-٩٦٦) +، ٢١٤٢٤٧٢ (١١-٩٦٦) +<br />فاكس: ٢٠٧٨١٧٠ (١١-٩٦٦) +<br />البريد الإلكتروني: jpimedical@hikma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">الشركة العربية لصناعة الأدوية المساهمة الخاصة<br />سحاب<br />المدينة الصناعية<br />صندوق بريد ٤١<br />عمان ١١٥١٢، الأردن<br />هاتف: ٤٠٢٣٩١٦ (٦-٩٦٢) +<br />فاكس: ٤٠٢٣٩١٧ (٦-٩٦٢) +</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul><li dir="RTL">&nbsp; &nbsp; المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul><li dir="RTL">&nbsp; &nbsp; دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ ٢٠٢٠/٠٩؛ رقم النسخة SA1.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Papillio 125 mg Hard Capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each hard capsule contains 125 mg palbociclib.

Excipients with known effect: Lactose and sodium.

Each 125 mg hard capsule contains 93.0 mg lactose. 

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule.

Polished hard capsules containing yellow to orange crystalline powder with caramel body/caramel cap imprinted in black with “SP01” logo on both body and cap.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Papillio is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer:</p><p>&middot;&nbsp;&nbsp;&nbsp; In combination with an aromatase inhibitor;</p><p>&middot;&nbsp;&nbsp;&nbsp; In combination with fulvestrant in women who have received prior endocrine therapy (see section 5.1).</p><p>&nbsp;</p><p>In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Papillio should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.</p><p>&nbsp;</p><p><u>Posology</u></p><p>The recommended dose is 125 mg of palbociclib once daily for 21 consecutive days followed by 7 days off treatment (Schedule 3/1) to comprise a complete cycle of 28 days. The treatment with Papillio should be continued as long as the patient is deriving clinical benefit from therapy or until unacceptable toxicity occurs.</p><p>When coadministered with palbociclib, the aromatase inhibitor should be administered according to the dose schedule reported in the Summary of Product Characteristics. Treatment of pre/perimenopausal women with the combination of palbociclib plus an aromatase inhibitor should always be combined with an LHRH agonist (see section 4.4).</p><p>&nbsp;</p><p>When coadministered with palbociclib, the recommended dose of fulvestrant is 500 mg administered intramuscularly on Days 1, 15, 29, and once monthly thereafter. Please refer to the Summary of Product Characteristics of fulvestrant. Prior to the start of treatment with the combination of palbociclib plus fulvestrant, and throughout its duration, pre/perimenopausal women should be treated with LHRH agonists according to local clinical practice.</p><p>&nbsp;</p><p>Patients should be encouraged to take their dose at approximately the same time each day. If the patient vomits or misses a dose, an additional dose should not be taken that day. The next prescribed dose should be taken at the usual time.</p><p>&nbsp;</p><p><em>Dose adjustments</em></p><p>Dose modification of Papillio is recommended based on individual safety and tolerability.</p><p>&nbsp;</p><p>Management of some adverse reactions may require temporary dose interruptions/delays, and/or dose reductions, or permanent discontinuation as per dose reduction schedules provided in Tables 1, 2, and 3 (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p><strong>Table 1. </strong><strong>Papillio </strong><strong>recommended dose modifications for adverse reactions</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Dose level</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Recommended dose</p></td><td style="vertical-align:top"><p>125 mg/day</p></td></tr><tr><td style="vertical-align:top"><p>First dose reduction</p></td><td style="vertical-align:top"><p>100 mg/day</p></td></tr><tr><td style="vertical-align:top"><p>Second dose reduction</p></td><td style="vertical-align:top"><p>75 mg/day*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>*If further dose reduction below 75 mg/day is required, discontinue the treatment.</p></td></tr></tbody></table><p>&nbsp;</p><p>Complete blood count should be monitored prior to the start of Papillio therapy and at the beginning of each cycle, as well as on Day 15 of the first 2 cycles, and as clinically indicated.</p><p>&nbsp;</p><p>For patients who experience a maximum of Grade 1 or 2 neutropenia in the first 6 cycles, complete blood counts for subsequent cycles should be monitored every 3 months, prior to the beginning of a cycle and as clinically indicated.</p><p>&nbsp;</p><p>Absolute neutrophil counts (ANC) of &ge; 1,000/mm<sup>3&nbsp;</sup>and platelet counts of &ge; 50,000/mm<sup>3</sup>&nbsp;are recommended to receive Papillio.</p><p>&nbsp;</p><p><strong>Table 2. </strong><strong>Papillio</strong> <strong>dose modification and management &ndash; Haematological toxicities</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>CTCAE grade</strong></p></td><td style="vertical-align:top"><p><strong>Dose modifications</strong></p></td></tr><tr><td style="vertical-align:top"><p>Grade 1 or 2</p></td><td style="vertical-align:top"><p>No dose adjustment is required.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 3<sup>a</sup></p></td><td style="vertical-align:top"><p><u>Day 1 of cycle</u>:</p><p>Withhold Papillio, until recovery to Grade &le; 2, and repeat complete blood count monitoring within 1 week. When recovered to Grade &le; 2, start the next cycle at the&nbsp;<em>same dose</em>.</p><p><u>Day 15 of first 2 cycles</u>:</p><p>If Grade 3 on Day 15, continue Papillio at the&nbsp;<em>current dose</em>&nbsp;to complete cycle and repeat complete blood count on Day 22.</p><p>If Grade 4 on Day 22, see Grade 4 dose modification guidelines below.</p><p>Consider dose reduction in cases of prolonged (&gt; 1 week) recovery from Grade 3 neutropenia or recurrent Grade 3 neutropenia on Day 1 of subsequent cycles.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 3 ANC<sup>b</sup></p><p>(&lt;1,000 to 500/mm<sup>3</sup>) + Fever &ge; 38.5 &deg;C and/or infection</p></td><td style="vertical-align:top"><p>At any time:</p><p>Withhold Papillio until recovery to Grade &le; 2</p><p>Resume at next lower dose.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 4<sup>a</sup></p></td><td style="vertical-align:top"><p>At any time:</p><p>Withhold Papillio until recovery to Grade &le; 2.</p><p>Resume at next lower dose.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Grading according to CTCAE 4.0.</p><p>ANC=absolute neutrophil counts; CTCAE=Common Terminology Criteria for Adverse Events; LLN=lower limit of normal.</p><p><sup>a</sup>&nbsp;Table applies to all haematological adverse reactions except lymphopenia (unless associated with clinical events, e.g., opportunistic infections).</p><p><sup>b</sup>&nbsp;ANC: Grade 1: ANC &lt; LLN &ndash; 1,500/mm<sup>3</sup>; Grade 2: ANC 1,000 - &lt; 1,500/mm<sup>3</sup>; Grade 3: ANC 500 - &lt; 1,000/mm<sup>3</sup>; Grade 4: ANC &lt; 500/mm<sup>3</sup>.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Table 3. </strong><strong>Papillio </strong><strong>dose modification and management &ndash; Non-haematological toxicities</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p><strong>CTCAE grade</strong></p></td><td style="vertical-align:bottom"><p><strong>Dose modifications</strong></p></td></tr><tr><td style="vertical-align:top"><p>Grade 1 or 2</p></td><td style="vertical-align:top"><p>No dose adjustment is required.</p></td></tr><tr><td style="vertical-align:top"><p>Grade &ge; 3 non-haematological toxicity (if persisting despite medical treatment)</p></td><td style="vertical-align:top"><p>Withhold until symptoms resolve to:</p><p>&bull; Grade &le; 1;</p><p>&bull; Grade &le; 2 (if not considered a safety risk for the patient)</p><p>Resume at the next lower dose.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Grading according to CTCAE 4.0.</p><p>CTCAE=Common Terminology Criteria for Adverse Events.</p></td></tr></tbody></table><p>&nbsp;</p><p>Permanently discontinue Papillio in patients with severe interstitial lung disease (ILD)/pneumonitis (see section 4.4).</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Elderly</em></p><p>No dose adjustment of Papillio is necessary in patients &ge; 65 years of age (see section 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment of Papillio is required for patients with mild or moderate hepatic impairment (Child-Pugh classes A and B). For patients with severe hepatic impairment (Child-Pugh class C), the recommended dose of Papillio is 75 mg once daily on Schedule 3/1 (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment of Papillio is required for patients with mild, moderate or severe renal impairment (creatinine clearance [CrCl] &ge; 15 mL/min). Insufficient data are available in patients requiring haemodialysis to provide any dose adjustment recommendation in this patient population (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of palbociclib in children and adolescents &lt; 18 years of age have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Papillio is for oral use. It should be taken with food, preferably a meal to ensure consistent palbociclib exposure (see section 5.2). Palbociclib should not be taken with grapefruit or grapefruit juice (see section 4.5).</p><p>&nbsp;</p><p>Papillio Capsules should be swallowed whole (should not be chewed, crushed, or opened prior to swallowing). No capsule should be ingested if it is broken, cracked, or otherwise not intact.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Use of preparations containing St. John's Wort (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pre/perimenopausal women</u></p><p>Ovarian ablation or suppression with an LHRH agonist is mandatory when pre/perimenopausal women are administered Papillio in combination with an aromatase inhibitor, due to the mechanism of action of aromatase inhibitors. Palbociclib in combination with fulvestrant in pre/perimenopausal women has only been studied in combination with an LHRH agonist.</p><p>&nbsp;</p><p><u>Critical visceral disease</u></p><p>The efficacy and safety of palbociclib have not been studied in patients with critical visceral disease (see section 5.1).</p><p>&nbsp;</p><p><u>Haematological disorders</u></p><p>Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia. Appropriate monitoring should be performed (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p><u>Interstitial lung disease/pneumonitis</u></p><p>Severe, life-threatening, or fatal ILD and/or pneumonitis can occur in patients treated with Papillio when taken in combination with endocrine therapy.</p><p>&nbsp;</p><p>Across clinical trials (PALOMA-1, PALOMA-2, PALOMA-3), 1.4% of palbociclib-treated patients had ILD/pneumonitis of any grade, 0.1% had Grade 3, and no Grade 4 or fatal cases were reported. Additional cases of ILD/pneumonitis have been observed in the post-marketing setting, with fatalities reported (see section 4.8).</p><p>&nbsp;</p><p>Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis (e.g. hypoxia, cough, dyspnoea). In patients who have new or worsening respiratory symptoms and are suspected to have developed ILD/pneumonitis, interrupt Papillio immediately and evaluate the patient. Permanently discontinue Papillio in patients with severe ILD or pneumonitis (see section 4.2).</p><p>&nbsp;</p><p><u>Infections</u></p><p>Since Papillio has myelosuppressive properties, it may predispose patients to infections.</p><p>&nbsp;</p><p>Infections have been reported at a higher rate in patients treated with palbociclib in randomised clinical studies compared to patients treated in the respective comparator arm. Grade 3 and Grade 4 infections occurred respectively in 5.6% and 0.9% of patients treated with palbociclib in any combination (see section 4.8).</p><p>&nbsp;</p><p>Patients should be monitored for signs and symptoms of infection and treated as medically appropriate (see section 4.2).</p><p>&nbsp;</p><p>Physicians should inform patients to promptly report any episodes of fever.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>Administer Papillio with caution to patients with moderate or severe hepatic impairment, with close monitoring of signs of toxicity (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>Administer Papillio with caution to patients with moderate or severe renal impairment, with close monitoring of signs of toxicity (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>Concomitant treatment with inhibitors or inducers of CYP3A4</u></p><p>Strong inhibitors of CYP3A4 may lead to increased toxicity (see section 4.5). Concomitant use of strong CYP3A inhibitors during treatment with palbociclib should be avoided. Coadministration should only be considered after careful evaluation of the potential benefits and risks. If coadministration with a strong CYP3A inhibitor is unavoidable, reduce the Papillio dose to 75 mg once daily. When the strong inhibitor is discontinued, increase the Papillio dose (after 3-5 half-lives of the inhibitor) to the dose used prior to the initiation of the strong CYP3A inhibitor (see section 4.5).</p><p>&nbsp;</p><p>Coadministration of CYP3A inducers may lead to decreased palbociclib exposure and consequently a risk for lack of efficacy. Therefore, concomitant use of palbociclib with strong CYP3A4 inducers should be avoided. No dose adjustments are required for coadministration of palbociclib with moderate CYP3A inducers (see section 4.5).</p><p>&nbsp;</p><p><u>Women of childbearing potential or their partners</u></p><p>Women of childbearing potential or their male partners must use a highly effective method of contraception while taking Papillio (see section 4.6).</p><p>&nbsp;</p><p><u>Lactose</u></p><p>Papillio contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p><p><u>Sodium</u></p><p>Papillio contains sodium. Papillio contains less than 1 mmol sodium (23 mg) per hard capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Palbociclib is primarily metabolised by CYP3A and sulphotransferase (SULT) enzyme SULT2A1.&nbsp;<em>In vivo</em>, palbociclib is a weak, time-dependent inhibitor of CYP3A.</p><p>&nbsp;</p><p><u>Effects of other medicinal products on the pharmacokinetics of palbociclib</u></p><p><em>Effect of CYP3A inhibitors</em></p><p>Coadministration of multiple 200 mg doses of itraconazole with a single 125 mg palbociclib dose increased palbociclib total exposure (AUC<sub>inf</sub>) and the peak concentration (C<sub>max</sub>) by approximately 87% and 34%, respectively, relative to a single 125 mg palbociclib dose given alone.</p><p>&nbsp;</p><p>The concomitant use of strong CYP3A inhibitors including, but not limited to: clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, saquinavir, telaprevir, telithromycin, voriconazole, and grapefruit or grapefruit juice, should be avoided (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p>No dose adjustments are needed for mild and moderate CYP3A inhibitors.</p><p>&nbsp;</p><p><em>Effect of CYP3A inducers</em></p><p>Coadministration of multiple 600 mg doses of rifampin with a single 125 mg palbociclib dose decreased palbociclib AUC<sub>inf</sub>&nbsp;and C<sub>max</sub>&nbsp;by 85% and 70%, respectively, relative to a single 125 mg palbociclib dose given alone.</p><p>&nbsp;</p><p>The concomitant use of strong CYP3A inducers including, but not limited to: carbamazepine, enzalutamide, phenytoin, rifampin, and St. John&#39;s Wort should be avoided (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p>Coadministration of multiple 400 mg daily doses of modafinil, a moderate CYP3A inducer, with a single 125 mg palbociclib dose decreased palbociclib AUC<sub>inf</sub>&nbsp;and C<sub>max</sub>&nbsp;by 32% and 11%, respectively, relative to a single 125 mg palbociclib dose given alone. No dose adjustments are required for moderate CYP3A inducers (see section 4.4).</p><p>&nbsp;</p><p><u>Effect of acid reducing agents</u></p><p>Under fed conditions (intake of a moderate-fat meal), coadministration of multiple doses of the proton pump inhibitor (PPI) rabeprazole with a single dose of 125 mg palbociclib decreased palbociclib C<sub>max</sub>&nbsp;by 41%, but had limited impact on AUC<sub>inf</sub>&nbsp;(13% decrease) compared with a single dose of 125 mg palbociclib administered alone.</p><p>&nbsp;</p><p>Under fasting conditions, the coadministration of multiple doses of the proton pump inhibitor (PPI) rabeprazole with a single dose of 125 mg palbociclib decreased palbociclib AUC<sub>inf</sub>&nbsp;and C<sub>max</sub>&nbsp;by 62% and 80%, respectively. Therefore, palbociclib should be taken with food, preferably a meal (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p>Given the reduced effect on gastric pH of H2-receptor antagonists and local antacids compared to PPIs, no clinically relevant effect of H2-receptor antagonists or local antacids<strong>&nbsp;</strong>on palbociclib exposure is expected when palbociclib is taken with food.</p><p>&nbsp;</p><p><u>Effects of palbociclib on the pharmacokinetics of other medicinal products</u></p><p>Palbociclib is a weak, time-dependent inhibitor of CYP3A following daily 125 mg dosing at steady state. Coadministration of multiple doses of palbociclib with midazolam increased the midazolam AUC<sub>inf</sub>&nbsp;and C<sub>max</sub>&nbsp;values by 61% and 37%, respectively, as compared with administration of midazolam alone.</p><p>&nbsp;</p><p>The dose of sensitive CYP3A substrates with a narrow therapeutic index (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus) may need to be reduced when coadministered with palbociclib as palbociclib may increase their exposure.</p><p>&nbsp;</p><p><u>Drug-drug interaction between palbociclib and letrozole</u></p><p>Data from the drug-drug interaction (DDI) evaluation portion of a clinical study in patients with breast cancer showed that there was no drug interaction between palbociclib and letrozole when the 2 medicinal products were coadministered.</p><p>&nbsp;</p><p><u>Effect of tamoxifen on palbociclib exposure</u></p><p>Data from a DDI study in healthy male subjects indicated that palbociclib exposures were comparable when a single dose of palbociclib was coadministered with multiple doses of tamoxifen and when palbociclib was given alone.</p><p>&nbsp;</p><p><u>Drug-drug interaction between palbociclib and fulvestrant</u></p><p>Data from a clinical study in patients with breast cancer showed that there was no clinically relevant drug interaction between palbociclib and fulvestrant when the two medicinal products were coadministered.</p><p>&nbsp;</p><p><u>Drug-drug interaction between palbociclib and oral contraceptives</u></p><p>DDI studies of palbociclib with oral contraceptives have not been conducted (see section 4.6).</p><p>&nbsp;</p><p><em><u>In vitro</u></em><em>&nbsp;</em><u>studies with transporters</u></p><p>Based on&nbsp;<em>in vitro</em>&nbsp;data, palbociclib is predicted to inhibit intestinal P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) mediated transport. Therefore, administration of palbociclib with medicinal products that are substrates of P-gp (e.g., digoxin, dabigatran, colchicine) or BCRP (e.g., pravastatin, rosuvastatin, sulfasalazine) may increase their therapeutic effect and adverse reactions.</p><p>&nbsp;</p><p>Based on&nbsp;<em>in vitro</em>&nbsp;data, palbociclib may inhibit the uptake transporter organic cationic transporter OCT1 and then may increase the exposure of medical product substrates of this transporter (e.g., metformin).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception</u></p><p>Females of childbearing potential who are receiving this medicinal product, or their male partners should use adequate contraceptive methods (e.g., double-barrier contraception) during therapy and for at least 3 weeks or 14 weeks after completing therapy for females and males, respectively (see section 4.5).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>There are no or limited amount of data from the use of palbociclib in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Papillio is not recommended during pregnancy and in women of childbearing potential not using contraception.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>No studies have been conducted in humans or animals to assess the effect of palbociclib on milk production, its presence in breast milk, or its effects on the breast-fed child. It is unknown whether palbociclib is excreted in human milk. Patients receiving palbociclib should not breast feed.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There were no effects on oestrous cycle (female rats) or mating and fertility in rats (male or female) in non-clinical reproductive studies. However, no clinical data have been obtained on fertility in humans. Based on male reproductive organ findings (seminiferous tubule degeneration in testis, epididymal hypospermia, lower sperm motility and density, and decreased prostate secretion) in nonclinical safety studies, male fertility may be compromised by treatment with palbociclib (see section 5.3). Thus, men may consider sperm preservation prior to beginning therapy with Papillio.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Papillio has minor influence on the ability to drive and use machines. However, palbociclib may cause fatigue and patients should exercise caution when driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The overall safety profile of palbociclib is based on pooled data from 872 patients who received palbociclib in combination with endocrine therapy (N=527 in combination with letrozole and N=345 in combination with fulvestrant) in randomised clinical studies in HR-positive, HER2-negative advanced or metastatic breast cancer.</p><p>&nbsp;</p><p>The most common (&ge; 20%) adverse reactions of any grade reported in patients receiving palbociclib in randomised clinical studies were neutropenia, infections, leukopenia, fatigue, nausea, stomatitis, anaemia, diarrhoea, alopecia and thrombocytopenia. The most common (&ge; 2%) Grade &ge; 3 adverse reactions of palbociclib were neutropenia, leukopenia, infections, anaemia, aspartate aminotransferase (AST) increased, fatigue, and alanine aminotransferase (ALT) increased.</p><p>&nbsp;</p><p>Dose reductions or dose modifications due to any adverse reaction occurred in 38.4% of patients receiving palbociclib in randomised clinical studies regardless of the combination.</p><p>&nbsp;</p><p>Permanent discontinuation due to an adverse reaction occurred in 5.2% of patients receiving palbociclib in randomised clinical studies regardless of the combination.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Table 4 reports the adverse reactions from the pooled dataset of 3 randomised studies. The median duration of palbociclib treatment across the pooled dataset at the time of the final overall survival (OS) analysis was 14.8 months.</p><p>&nbsp;</p><p>Table 5 reports the laboratory abnormalities observed in pooled datasets from 3 randomised studies.</p><p>&nbsp;</p><p>The adverse reactions are listed by system organ class and frequency category. Frequency categories are defined as: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), and uncommon (&ge; 1/1,000 to &lt; 1/100). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 4. Adverse reactions based on pooled dataset from 3 randomised studies (N=872)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p><p><strong>Frequency</strong></p><p><strong>Preferred term<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 4</strong></p><p><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p><p><em>Very common</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Infections<sup>b</sup></p></td><td style="vertical-align:top"><p>516 (59.2)</p></td><td style="vertical-align:top"><p>49 (5.6)</p></td><td style="vertical-align:top"><p>8 (0.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p><p><em>Very common</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Neutropenia<sup>c</sup></p></td><td style="vertical-align:top"><p>716 (82.1)</p></td><td style="vertical-align:top"><p>500 (57.3)</p></td><td style="vertical-align:top"><p>97 (11.1)</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia<sup>d</sup></p></td><td style="vertical-align:top"><p>424 (48.6)</p></td><td style="vertical-align:top"><p>254 (29.1)</p></td><td style="vertical-align:top"><p>7 (0.8)</p></td></tr><tr><td style="vertical-align:top"><p>Anaemia<sup>e</sup></p></td><td style="vertical-align:top"><p>258 (29.6)</p></td><td style="vertical-align:top"><p>45 (5.2)</p></td><td style="vertical-align:top"><p>2 (0.2)</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>f</sup></p></td><td style="vertical-align:top"><p>194 (22.2)</p></td><td style="vertical-align:top"><p>16 (1.8)</p></td><td style="vertical-align:top"><p>4 (0.5)</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td style="vertical-align:top"><p>12 (1.4)</p></td><td style="vertical-align:top"><p>10 (1.1)</p></td><td style="vertical-align:top"><p>2 (0.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p><p><em>Very common</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>152 (17.4)</p></td><td style="vertical-align:top"><p>8 (0.9)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Dysgeusia</p></td><td style="vertical-align:top"><p>79 (9.1)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Vision blurred</p></td><td style="vertical-align:top"><p>48 (5.5)</p></td><td style="vertical-align:top"><p>1 (0.1)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:top"><p>Lacrimation increased</p></td><td style="vertical-align:top"><p>59 (6.8)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:top"><p>Dry eye</p></td><td style="vertical-align:top"><p>36 (4.1)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p><p><em>Common</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Epistaxis</p><p>ILD/pneumonitis<sup>*,i</sup></p></td><td style="vertical-align:top"><p>77 (8.8)</p><p>12 (1.4)</p></td><td style="vertical-align:top"><p>0 (0.0)</p><p>1 (0.1)</p></td><td style="vertical-align:top"><p>0 (0.0)</p><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p><p><em>Very common</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Stomatitis<sup>g</sup></p></td><td style="vertical-align:top"><p>264 (30.3)</p></td><td style="vertical-align:top"><p>8 (0.9)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>314 (36.0)</p></td><td style="vertical-align:top"><p>5 (0.6)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>238 (27.3)</p></td><td style="vertical-align:top"><p>9 (1.0)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>165 (18.9)</p></td><td style="vertical-align:top"><p>6 (0.7)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p><p><em>Very common</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Rash<sup>h</sup></p></td><td style="vertical-align:top"><p>158 (18.1)</p></td><td style="vertical-align:top"><p>7 (0.8)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>234 (26.8)</p></td><td style="vertical-align:top"><p>N/A</p></td><td style="vertical-align:top"><p>N/A</p></td></tr><tr><td style="vertical-align:top"><p>Dry skin</p></td><td style="vertical-align:top"><p>93 (10.7)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p><p><em>Very common</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>362 (41.5)</p></td><td style="vertical-align:top"><p>23 (2.6)</p></td><td style="vertical-align:top"><p>2 (0.2)</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>118 (13.5)</p></td><td style="vertical-align:top"><p>14 (1.6)</p></td><td style="vertical-align:top"><p>1 (0.1)</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>115 (13.2)</p></td><td style="vertical-align:top"><p>1 (0.1)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p><p><em>Very common</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>ALT increased</p></td><td style="vertical-align:top"><p>92 (10.6)</p></td><td style="vertical-align:top"><p>18 (2.1)</p></td><td style="vertical-align:top"><p>1 (0.1)</p></td></tr><tr><td style="vertical-align:top"><p>AST Increased</p></td><td style="vertical-align:top"><p>99 (11.4)</p></td><td style="vertical-align:top"><p>25 (2.9)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>ALT=alanine aminotransferase; AST=aspartate aminotransferase; ILD=interstitial lung disease; N/n=number of patients; N/A=not applicable.</p><p><sup>*</sup>&nbsp;Adverse Drug Reaction (ADR) identified post-marketing.</p><p><sup>a</sup>&nbsp;Preferred Terms (PTs) are listed according to MedDRA 17.1.</p><p><sup>b</sup>&nbsp;Infections includes all PTs that are part of the System Organ Class Infections and infestations.</p><p><sup>c</sup>&nbsp;Neutropenia includes the following PTs: Neutropenia, Neutrophil count decreased.</p><p><sup>d</sup>&nbsp;Leukopenia includes the following PTs: Leukopenia, White blood cell count decreased.</p><p><sup>e</sup>&nbsp;Anaemia includes the following PTs: Anaemia, Haemoglobin decreased, Haematocrit decreased.</p><p><sup>f</sup>&nbsp;Thrombocytopenia includes the following PTs: Thrombocytopenia, Platelet count decreased.</p><p><sup>g</sup>&nbsp;Stomatitis includes the following PTs: Aphthous stomatitis, Cheilitis, Glossitis, Glossodynia, Mouth ulceration, Mucosal inflammation, Oral pain, Oropharyngeal discomfort, Oropharyngeal pain, Stomatitis.</p><p><sup>h</sup>&nbsp;Rash includes the following PTs: Rash, Rash maculo-papular, Rash pruritic, Rash erythematous, Rash papular, Dermatitis, Dermatitis acneiform, Toxic skin eruption.</p><p><sup>i</sup>&nbsp;ILD/pneumonitis includes any reported PTs that are part of the Standardised MedDRA Query Interstitial Lung Disease (narrow).</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Table 5. Laboratory abnormalities observed in pooled dataset from 3 randomised studies (N=872)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="3" style="vertical-align:top"><p><strong>Palbociclib plus letrozole or fulvestrant</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Comparator arms*</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Laboratory abnormalities</strong></p></td><td style="vertical-align:top"><p><strong>All grades</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>grade 3</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>grade 4</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>All grades</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>grade 3</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>grade 4</strong></p><p><strong>%</strong></p></td></tr><tr><td style="vertical-align:top"><p>WBC decreased</p></td><td style="vertical-align:top"><p>97.4</p></td><td style="vertical-align:top"><p>41.8</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>26.2</p></td><td style="vertical-align:top"><p>0.2</p></td><td style="vertical-align:top"><p>0.2</p></td></tr><tr><td style="vertical-align:top"><p>Neutrophils decreased</p></td><td style="vertical-align:top"><p>95.6</p></td><td style="vertical-align:top"><p>57.5</p></td><td style="vertical-align:top"><p>11.7</p></td><td style="vertical-align:top"><p>17.0</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>80.1</p></td><td style="vertical-align:top"><p>5.6</p></td><td style="vertical-align:top"><p>N/A</p></td><td style="vertical-align:top"><p>42.1</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>N/A</p></td></tr><tr><td style="vertical-align:top"><p>Platelets decreased</p></td><td style="vertical-align:top"><p>65.2</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>13.2</p></td><td style="vertical-align:top"><p>0.2</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>AST increased</p></td><td style="vertical-align:top"><p>55.5</p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>0.0</p></td><td style="vertical-align:top"><p>43.3</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>ALT increased</p></td><td style="vertical-align:top"><p>46.1</p></td><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>33.2</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>0.0</p></td></tr></tbody></table><p>WBC-white blood cells; AST-aspartate aminotransferase; ALT-alanine aminotransferase; N-number of patients; N/A-not applicable.</p><p>Note: Laboratory results are graded according to the NCI CTCAE version 4.0 severity grade.</p><p>* letrozole or fulvestrant</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>Overall, neutropenia of any grade was reported in 716 (82.1%) patients receiving palbociclib regardless of the combination, with Grade 3 neutropenia being reported in 500 (57.3%) patients, and Grade 4 neutropenia being reported in 97 (11.1 %) patients (see Table 4).</p><p>&nbsp;</p><p>The median time to first episode of any grade neutropenia was 15 days (12-700 days) and the median duration of Grade &ge; 3 neutropenia was 7 days across 3 randomised clinical studies.</p><p>&nbsp;</p><p>Febrile neutropenia has been reported in 0.9% of patients receiving palbociclib in combination with fulvestrant and in 1.7% of patients receiving palbociclib in combination with letrozole.</p><p>&nbsp;</p><p>Febrile neutropenia has been reported in about 2% of patients exposed to palbociclib across the overall clinical programme.</p><p><strong>&nbsp;</strong></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&middot;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Center (NPC)</p><p>Fax: + (966-11) 2057662</p><p>Call NPC at: + (966-11) 2038222, Exts: 2317-2356-2340.</p><p>SFDA Call Center: 19999</p><p>e-mail: npc.drug@sfda.gov.sa</p><p>Website: <u>https://ade.sfda.gov.sa</u></p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of a palbociclib overdose, both gastrointestinal (e.g., nausea, vomiting) and haematological (e.g., neutropenia) toxicity may occur and general supportive care should be provided.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01XE33.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Palbociclib is a highly selective, reversible inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Cyclin D1 and CDK4/6 are downstream of multiple signalling pathways which lead to cellular proliferation.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Through inhibition of CDK4/6, palbociclib reduced cellular proliferation by blocking progression of the cell from G1 into S phase of the cell cycle. Testing of palbociclib in a panel of molecularly profiled breast cancer cell lines revealed high activity against luminal breast cancers, particularly ER-positive breast cancers. In the cell lines tested, the loss of retinoblastoma (Rb) was associated with loss of palbociclib activity. However, in a follow-up study with fresh tumour samples, no relation between RB1 expression and tumour response was observed. Similarly, no relation was observed when studying the response to palbociclib in&nbsp;<em>in vivo&nbsp;</em>models with patient-derived xenografts (PDX models). Available clinical data are reported in the clinical efficacy and safety section (see section 5.1).</p><p>&nbsp;</p><p><u>Cardiac electrophysiology</u></p><p>The effect of palbociclib on the QT interval corrected for heart rate (QTc) interval was evaluated using time matched electrocardiogram (ECG) evaluating the change from baseline and corresponding pharmacokinetic data in 77 patients with advanced breast cancer. Palbociclib did not prolong the QTc to any clinically relevant extent at the recommended dose of 125 mg daily (Schedule 3/1).</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><em>Randomised Phase 3 Study PALOMA-2: Palbociclib in combination with letrozole</em></p><p>The efficacy of palbociclib in combination with letrozole versus letrozole plus placebo was evaluated in an international, randomised, double-blind, placebo-controlled, parallel-group, multicentre study conducted in women with ER-positive, HER2-negative locally advanced breast cancer not amenable to resection or radiation therapy with curative intent or metastatic breast cancer who had not received prior systemic treatment for their advanced disease.</p><p>&nbsp;</p><p>A total of 666 postmenopausal women were randomised 2:1 to the palbociclib plus letrozole arm or placebo plus letrozole arm and were stratified by site of disease (visceral versus nonvisceral), disease-free interval from the end of (neo)adjuvant treatment to disease recurrence (<em>de novo</em>&nbsp;metastatic versus &le; 12 months versus &gt; 12 months), and by the type of prior (neo)adjuvant anticancer therapies (prior hormonal therapy versus no prior hormonal therapy). Patients with advanced symptomatic, visceral spread, that were at risk of life-threatening complications in the short term (including patients with massive uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary lymphangitis, and over 50% liver involvement), were not eligible for enrolment into the study.</p><p>&nbsp;</p><p>Patients continued to receive assigned treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first. Crossover between treatment arms was not allowed.</p><p>&nbsp;</p><p>Patients were well matched for baseline demographics and prognostic characteristics between the palbociclib plus letrozole arm and the placebo plus letrozole arm. The median age of patients enrolled in this study was 62 years (range 28-89), 48.3% of patients had received chemotherapy and 56.3% had received antihormonal therapy in the (neo)adjuvant setting prior to their diagnosis of advanced breast cancer while 37.2% of patients had received no prior systemic therapy in the (neo)adjuvant setting. The majority of patients (97.4%) had metastatic disease at baseline, 23.6% of patients had bone-only disease, and 49.2% of patients had visceral disease.</p><p>&nbsp;</p><p>The primary endpoint of the study was progression-free survival (PFS) evaluated according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1, as assessed by investigator. Secondary efficacy endpoints included objective response (OR), clinical benefit response (CBR), safety, and change in quality of life (QoL).</p><p>&nbsp;</p><p>At the data cutoff date of 26-February-2016, the study met its primary objective of improving PFS. The observed hazard ratio (HR) was 0.576 (95% confidence interval [CI]: 0.46, 0.72) in favour of palbociclib plus letrozole, with a stratified log-rank test 1-sided p-value of &lt; 0.000001. An updated analysis of the primary and secondary endpoints was performed after an additional 15 months of follow up (data cutoff date: 31-May-2017). A total of 405 PFS events were observed; 245 events (55.2%) in the palbociclib plus letrozole arm and 160 (72.1%) in the comparator arm respectively.</p><p>&nbsp;</p><p>Table 6 shows the efficacy results based on the primary and the updated analyses from the PALOMA-2 study, as assessed by the investigator and by the independent review.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="7"><p><strong>Table 6. PALOMA-2 (intent-to-treat population) - Efficacy results based on primary and updated cutoff dates</strong></p></td></tr><tr><td>&nbsp;</td><td colspan="3"><p><strong>Primary analysis</strong></p><p><strong>(26 February 2016 cutoff)</strong></p></td><td colspan="3"><p><strong>Updated analysis</strong></p><p><strong>(31 May 2017 cutoff)</strong></p></td></tr><tr><td>&nbsp;</td><td><p><strong>Palbociclib plus letrozole</strong></p><p><strong>(N = 444)</strong></p></td><td colspan="2"><p><strong>Placebo</strong></p><p><strong>plus letrozole</strong></p><p><strong>(N = 222)</strong></p></td><td><p><strong>Palbociclib plus letrozole</strong></p><p><strong>(N = 444)</strong></p></td><td colspan="2"><p><strong>Placebo</strong></p><p><strong>plus letrozole</strong></p><p><strong>(N = 222)</strong></p></td></tr><tr><td colspan="7"><p><strong>Progression-free survival by investigator assessment</strong></p></td></tr><tr><td><p>Number of events (%)</p></td><td><p>194 (43.7)</p></td><td colspan="2"><p>137 (61.7)</p></td><td><p>245 (55.2)</p></td><td colspan="2"><p>160 (72.1)</p></td></tr><tr><td><p>Median PFS [months (95% CI)]</p></td><td><p>24.8 (22.1, NE)</p></td><td colspan="2"><p>14.5 (12.9, 17.1)</p></td><td><p>27.6 (22.4, 30.3)</p></td><td colspan="2"><p>14.5 (12.3, 17.1)</p></td></tr><tr><td><p>Hazard ratio [(95% CI) and p-value]</p></td><td colspan="3"><p>0.576 (0.463, 0.718), p&lt; 0.000001</p></td><td colspan="3"><p>0.563 (0.461, 0.687), p&lt; 0.000001</p></td></tr><tr><td colspan="7"><p><strong>Progression-free survival by independent assessment</strong></p></td></tr><tr><td><p>Number of events (%)</p></td><td colspan="2"><p>152 (34.2)</p></td><td><p>96 (43.2)</p></td><td><p>193 (43.5)</p></td><td colspan="2"><p>118 (53.2)</p></td></tr><tr><td><p>Median PFS [months (95% CI)]</p></td><td colspan="2"><p>30.5 (27.4, NE)</p></td><td><p>19.3 (16.4, 30.6)</p></td><td><p>35.7 (27.7, 38.9)</p></td><td colspan="2"><p>19.5 (16.6, 26.6)</p></td></tr><tr><td><p>Hazard ratio (95% CI) and 1-sided p-value</p></td><td colspan="3"><p>0.653 (0.505, 0.844), p=0.000532</p></td><td colspan="3"><p>0.611 (0.485, 0.769), p=0.000012</p></td></tr><tr><td><p><strong>OR*</strong>&nbsp;[% (95% CI)]</p></td><td><p>46.4 (41.7, 51.2)</p></td><td colspan="2"><p>38.3 (31.9, 45.0)</p></td><td><p>47.5 (42.8, 52.3)</p></td><td colspan="2"><p>38.7(32.3, 45.5)</p></td></tr><tr><td><p><strong>OR* measurable disease&nbsp;</strong>[% (95% CI)]</p></td><td><p>60.7 (55.2, 65.9)</p></td><td colspan="2"><p>49.1 (41.4, 56.9)</p></td><td><p>62.4 (57.0, 67.6)</p></td><td colspan="2"><p>49.7 (42.0, 57.4)</p></td></tr><tr><td><p><strong>CBR*&nbsp;</strong>[% (95% CI)]</p></td><td><p>85.8 (82.2, 88.9)</p></td><td colspan="2"><p>71.2 (64.7, 77.0)</p></td><td><p>85.6 (82.0, 88.7)</p></td><td colspan="2"><p>71.2 (64.7, 77.0)</p></td></tr><tr><td colspan="6"><p>N=number of patients; CI=confidence interval; NE=not estimable; OR=objective response; CBR=clinical benefit response; PFS=progression-free survival.</p><p>* Secondary endpoints results are based on confirmed and unconfirmed responses according to RECIST 1.1.</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>The Kaplan-Meier curves for PFS based on the updated cutoff date of 31 May 2017 are displayed in Figure 1 below.</p><p>&nbsp;</p><p><strong>Figure 1. Kaplan-Meier plot of progression-free survival (investigator assessment, intent-to-treat population) &ndash; PALOMA-2 study (31-May-2017)</strong></p><p><img alt="" width="451" height="325" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAcMAAAFFCAMAAAHQtka/AAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAADVUExURQAAAP////+2ZgAAOpDb/2a2////tmYAAABmttuQOgAAZrb/////25A6AP/bkDo6kNv//7ZmAGYAZjoAAGYAOjoAZpA6Zrb/tpA6OjqQ2zpmtmZmZgA6kGa229v/tjpmZra2ZpDb25CQZrb/2wBmZtu2ZgA6ZmY6AJC2kGaQkDqQkLbbkGZmOjoAOgA6Ov/b2zo6OraQOpCQOtvbkDqQttv/27ZmOjo6ZmY6Ojo6AABmkGZmAGY6kP/btrbb/5DbttuQZmZmttvb25BmkJBmZrZmZgAAAAACa5gAAABHdFJOU/////////////////////////////////////////////////////////////////////////////////////////////8Ax5xWbwAAAAlwSFlzAAAOwwAADsMBx2+oZAAAJXdJREFUeF7tXQujo7aZVTFgY2zGvkxmhsR5Nc1u02TStN3Obtrsdu8mo///k/Z7SALE+2nw5cxcLISkT0dHbzAWsgy/g39NKI/ZAuJuMS/k7gZt83VUw9jxItfxHOncvCRSfoNtCnnDtIpW4TJ4Rp6Q/kEckjBQ/gAdU6EYtxJWzA5xOaaUN/5AtIyrY3aHHZNOW6WmYzqdbRdKqHUR6ZjJiU47YGgJVUavSdfEzOWW6lwDqmy2jYkO9WmQ9SjLA8d8S+562HGNzc5IeVYkUZlyVQk1o11MUUJKe31ieqa2GJrbUPqz2+yDOWPqCGlMchhv+Ds/4QFdV3PIlMgUufXEMYx2rvy7OreBMX/vxVd5PQo3vF6l+7O60gSM6Tr4cZI7KWO5u+IhBkI7X+7lcwyncMABLUMSoGIGAgP4EP05kr6UB7h0deEA4aEbx1MAJK0OgGqeTRg9pp5J2fMpdY4f/U2qz864U8TjU0gnFdhJR8bRNTokZ5hKKWDEPTu7ASPCH1aUknxzPwlTukAEh3CXZAKgc4hF7WwPFRqrc7eo3cxkgBFTjh2SGWSxGLlFchik8yCCwIgVOtabLbtq/OqiKosJn2nUGyNgENWPlaIyiRZpl4epiZi/ZE8o8OzMzm7AiDVWq4GRTHdQiopk0fvKzhqURO6VTQRGHLuu1mNQxF6YyWImtO2Eg/6UZ1z72rMk3ZTopA8qIzoiidxD1SQJIzpHJxSBPOyEE7q71jkQMniSl5N8QzOkCA/kwsnR7oQTILwW8Whm5jkAiCiOtwTjCPmMU6tnnHfT3IirIrnU1CoXsSfmj9gX/SdzffGiLIqTlE+v3M57Gp0xEkcR7T1Bid28CJPcCZj34XmmWTCMxb17VC5E54zkBoNP1WcprKS9GUv1lDPdlWIHpKWKm6JBxlTngm2J1KL6nBytLI7Ktlh2FcmPZrVJrfQyzB5HsWpSoV2RJoxhM00DHQevdFqXtzPQqrHYVFctq/3ZphbR8a5m6lpuorvhvMXu6M7VxBCtuoBqA60tpxxxt+MVu+sBUaqSR3mbTBuLPAdui2qujRgQFdhURsbuQkH5GKQ+tP/XXg6F7jk2MXrWVUaXuGkeydH9blEObSynHNXKYnIYi+fvlWMwGojays84s7rK7OxxQqQ68kdDkYwAu1Snx6QWKW3bQJ1Fuq3P11/TEUFVC2/ewOQWgBuBtKmbOcBS4xXGoPgXx9pKu1OpOrS/xpvzmOkPaW/gqh30FJ4jxC5xo+g/d4c+vUaR49SNhCzCcsOR7uWANIUAfXwUyUcGPkoW4mnogjNEv/DJhwOsF+UzKvrsokvAlQ/uM8aFA96MwnglUBZD5/r6FshPVHLPH4MLJAKXntHis4+1hMv7Fzhimh/w8wO6AnNqG0sPGdyp5syLDhbxxpp9z60WEDgTXjsXzXEkbBanwEuyGNFwNweUxQC64zfy9MqdnrQywBOr6DX2u917vlhcolgkn8WxG8UHT8be137kyMiJveIQOgqlOBER/MlbDJ+fYQ7kF1LENwGOArTXKJZbodRid/M0p8JnR/iAMA4LKvFA4PrxRDq2RbokjfeeOEIx7sMECvJzP4BJhB8LykYBeTpQVw06EK2iUwqV7h7yaKGDxU7Q6YrSx1ynsFrKcdK5iE47wKkaTCItTGA6l+QJ+os84PLYhE1y1XPxqSwWMLIhg2qOU1ss6WwyAo6pZS6pVwdcv0wMZWHPK9nqBzXGy0nrlEYrWM2x2K8qjEdOQSdYaTGLUazrRELqbbKjlUFqZ1SLV/riQKcRuSe0xfLxegr0szik4uZLtQv6GtXxuK7OqSNbLK2rBgOKMoO8xc7okQkV5bqvezCwHh2taosH6wHGUlRU0W4mc6GD+of8qoBp6L9m6FA+6hgUZlYlUDP/MrRqpjqMGKtdNBo1FrvVnIZ06y7ra32+61aNFhb3hSd3GqGXcmWgawTlkYG2SD2AmHFmxTu/xXVHE1rVzjx0jJ69XA/c0WKbXq4GVEu69QB0rB+tGtHJImOEEbnRqA5wnV3Hy7Dy7ABtsWO/OgDaIo1WxzlnVoSngXXVIJeqBVOqs9cc+4sa06GO/zQwFqlU+82sukFb5EraZmY1FHcrVbXXMQfuWHM0SEk6UL+HricsgKcrSP2Ed34oCh9wVKWpisBv3uBtdnYFGCPBGNmv2jFsD4e+tIOHK7l+gD96qOLpz2D86QYHeuTiNT5bxw9fcHXDA16VV8gFmo4SiBElhWlpIQuTY/kWHeldZHSV3n+88oP4uI+PXefWaNHD5s/dDd0xw0dKcRD5AC778VKwSLcOk8SN+lsMQ//oOlexk5f3oLwbiZ/2LszMdkDm+9HnBvfREf4uUFw89wvfgJMO3hEOwDXC00h6LhzcEA9Y8CQFPctCLixsSmBH37VGn4rnfclKkFx80BGCBPIgQD9otx/ks4OPpISwJIFTei4FDgmvUHz5C3YQNKg+g4seYDmhfcqEepSlFMwRzMDH+YAEsCbQeYgH/hIGfjeKgmDNIioC0xPI5w0e6OtWFr0KohgSOhrdM0A6VEaY3oFcVIcx1Ef4O2GnQix8DEEPDeGzQNLHqxa99JADWZwVm8UpML/FmdH8vPnqsVF8BGwUHwE2RQc31nC8fRy8xIoaqE2yJ3zRGr9rbeWFYFMMaAYIeIKFsQf/wQmz0lYbtOMg8vJPh0Ww2OWWg/6n3DZlPmQFCipCY1Qk8xiXJrb4DNgzlvvAFUhxH4Q+3j2LA3yvQRx5fnLFMxco+glcTPiIPo0oUKzE9Dq20qQ7Sij6VT3qjLV1TBQowpKw8nmHXLUaH7FIIu8qLgH2cx6cUaEeQF0hzuKLL49wGgsXj12K26a43wu9RX47JdjdTEfJRnyBhngMPAGNTB7xLHFcpBglwTfQBvH0GuIRfWj93AYFiqCSonjVg4aBOZuN9Rho390AUopT1texUdYWK+/lFFmtgWeBIoyLlRRRvXz4VVI8+5riq5ML/9mdQ7aOrqDGFiiehH5s/SaT11Fpv1VCasE8bYqZHvVRUFDxSjedGrAqGQsU2w31ZRztrmgpKGQrnd3IKKxoiwrFngbOl8fSpgj1VLmkH2Knqk7aY3EcbYodu5sin+UNIkPbT1XsBTEdp4so5bMUjsXuJtIvdqNlGzubUc4RtLy/mkWKZsl/09tTbVBH5M4kixX1Kjp/y4FRy/KOatoUM6v+XmjgqVyzYkQVGc0s5iZaoDj4YWP1WY85BS2qaPCjwA3x7oVO7a4m3SzmIFqWFbWnXtye6oR2UWfg2LK0J8MMNdamuJe70V441KX4JqQ6rYqQduvkIScK+nwkFCmKt2qNePqh12KqiG6Z1QxTsgNRoAgLRn0LL5D1S+Ku6JpnCE5EBzItUNz74VhtsYCeeSWO+q87ihV1cvSXpV/MoopzbDL2JVmM1iIhmyIOGgoHv2F7agDuSTGHZJwetQ49uXbBHdpiDtr6hLkotkX1+Ti4t4pZcIc5en7KVFQ96nnYSqMvlEkc8hXYozdsitmNjde0Xrw/BnIsqHj+ftjGxgQYm2Ik/InGwnuh2BadZPrZTUcMk7FAMV1MLQfQ4wzodgoUM4spel6z93xyAlD/quhmHXxWBbiqXArn9HuO9NTt+lGgiDcYH6u/KaooxI9LGzWGoUARqrVyPAoKFDPdDT1ApVwrRllbTMfFyZbEc8KmmHli41FgU8QOdXGzmzKk2W7SpNjdPByaKUaXd8qFkwFG+pLuQLvf4DW6NwmuT/CTXKbDSigAuU74GgZy6R9V9UMdDtYAahngh/pOJ7rITRHJ9S7RNt4l2QyWoZmi76rEpGN+5jXr0lcNMTXxY9eNs4SXmCK6uFTAFfFUCoKrjg1cKm7epbo9+o0HQmJsJM5FZ6YcW0UdAY61cXCMfrqczWbtHr9j4+sqOQlmoejgD1fKXYCPugZelCTJLnD9QyyPRPE4bR4MReevTnj0vZ0435yfb1IkOHaIfwhX7sRlL/4u/uhehfPP43mHv9OHHi7M9dyziOiFDu1RMgE+zaOiE17D/Y/e0XFjoHgSN8y4OLyHmiUu4kcv/iPQ+TbcR0DxItEDyEfg9zd3vrcC9cL0FfXuMBQDeTi9lc4FBgk4wDSO++nTb/LXEA6Ao3Q/1S7hfqA3hEBl9ui3dvC1Kuqqc/rZ5Q7dgbrh0m+4OhCOX/DhyPDjr5T0M8TgcM8QQ/mdfsPYiB1EJgcnSAjSNsFvzGmDF6YijMiOuMnX0CMEwlOjLJY/F9mz9OVHenXLMyjL2sHBYz3xKqsI4ug3suxAMnY9a03e7fT7WkAS9YVXiKe/+no0b3Np0K7MVY6XpOLjYqP4CJiI4u/UT4jpzwIqL7SEil+ejOX7eBsZNjaG68fGcP3YGK4fG8P1Y2O4frw0hvjIw6NRbiS0esIvj+ErdYfH4NEYqjM/lMLD/w/HUOzkGWid3obR5R3fimysxktHgSHBDx155duiAoLMSDJW7yLUiPUL78g/d7PEClmFXO59fL4Gf1DAD333E74ZjNfhb3KS0cHxbviyM/iMoaijJPLgAIzhTB7wLYVyd5b7C56eDnAkHxW7BpY+QqtooK+PSJFG3RTsiS9Z3AE5/DzK/RF94EAM98QQcgYMJd6ApCP5NKOxBvJ1OI5IsQzRZ0LGfwDN4NMRXiAuER6QIX1bO/Ic4V5ve7wYCfEtHNGHI9ehLcPJt1ZbtqruyDP0iw+5m+sTM5wMBQ33lsdaiRnYGqY3KBXMddMnTIf0RahpnSVX7ocbOtZni6EnA+t3YLIMEepsdFBPI6GViAOYUv0NjMjYn3wubvv4K+xhdtjPgE8HkvkspxScy7t0PFRg53CSVFIA5WJPHCViGYsglIEQ3/GYAa7IgyB6lAhcGiVMpDbIhfX/BHG5kjqXM85pMmkVHaMiusFgeA2F4+2jJPgez2A8Rw1jeUSGeHrEI/moWC1QXRpXNS/ls6mIGcwzWvggmdKwuLaYmOFkqKqlBiXE1sW1upYqmOuZgCj1anhaDM+FSU0ZQ8JaOOYZ+om0X9ScMrQIrYOfle9sT6ORYbgWTnlY2a5hiNfW0/pS5Bn63k0/tY6Tp9xowcidroJunuEp2SsN050oOk2RPSdV8ZPOFgqrlhqoWVt97vma5rlQWJkzo4VzuRZm3gptfBaEPMO60cKghM+SKeYY1o4WBmtmWIZHY1jsNFplfj0M/QNteWex5My3gqVZkPniLKOEYUnNXvCIYWlY3B0ozTjerlHODJbJ0mKY6Uszd2ZKUcZn+QwziC7WTlQRJZcWSDHPIPMbfE/q26SPxdBP0h9IA0fZ2qIJy6OYZwiVsnlOU4faWn0fNOaoY46xjJbFchDDymtLIpnLSp9aWnF9oQzL0JzVcsEWQzGfu1N3DSuwnHqaz4jvvdc3SCt2oloD4mGdV2d3hJWHT/Q7owLajALH0DzenaOloTm7XswzUS1wdxo1sOuR/kkzoNcw886iLtC9d5GrGBq0zF5di8P2eD+eVbXUoEPG6oMugmHLO6SVqBMSlVSueTGmhk2B78PRNtq3HbYF2puX58gM24SeWcq8tahoe3yGM1PMG0t3ok6uemFUR4btKOY+JkZVlpz40LgTVQaIAFFaRpqFYpWGMDPtNS9VwTtpOS0KWTF3uZNha4s2uAPDrIYKPXPRKhpW6MnRaGNKhi0r8zDkbQgQUTk1JmWoMSXRHCM/ubrNd7nboYs8k9ZWS0MQUTk1etuGlFvHNbnoba0ajaXXn6E5tALoSFA56m22gGqGI40W3eIzSXLQ+QiwUroe9WtH9YtC52UIwSlHrCZ7DUSeoZ88qd3E6JJ02ImqA2cWD12AEZgrn/eHZTiTkaTPzLsamZTbgYulc7QCrATSWqoxFkPbUhtgDKRIMftSzcdLa6lBz3RL0D+HIzKEUzudnumWAKudcvbCOAyLGI8hYkDD6hsxH+1UfFnsuAyHoHfJKAdhvNVTHfomqRpkJn6blHIM/cQpfLG2b3ZqQFUVDHdMWkXLQ12rQRVDRz6NOx6WoGvSY2iIpaJqaeD12onqhCnTNqhm0G8nanmwGZrfD5xhJwprzPQF2GhiDg0ntWExTNuhxhwMJzWSZ+hjvcxjFoZTwmJ4Jw2nNLOIdogYOi+vRLEdKpfGXAwZaB/+UrrDzecZpd9GOA19JmoYkKWC8ukNK4XMtxHuO+IbDcdlmH0Ww3dH2okaiMEUqxKIwl73gCfAuAxPx3jiZzG6Y1yGvrebbieqJ8ZlKGNvst3EvhiZ4avMj2Yw7s5wKOxaKh68lp7EMX1XE+PBGE65q98XkEOa2vTNiFVL0139Pb46ET7vzlBjHIZYWspFr7/MnN8dKCRKWTwgVKASVF7z8RWm8LkYhnU5ac8ws6vPr6FdEsOeyDO83xp/OhQZWl92fjCGMpGBNeQ/GEP8ZlecX1w8moZFPBrDgN5om8WDMcy/F+MRRws4Tc8f8t5T7r0Yy9iJGgyLYXbEX9jMuy+sWlrEgzHMvBdD47EYZt+LoZFeX5KrA/IMoRlWz7yX5OqADu1wSa4OaGS4ejQx1N/Pl/JqXEHRzw/xdhy7pFqAoYv88BKcKBesX9gVKNvQu6kOLu/i9FI/mWgbAXizjSCTmQo0MXx1Ms+BcSYB6dQ1Ue7TW7hG35jCH3DhcPxTLuSUAQUgl3ynokNwlfMnE+6J/pNLf/8KXezGiGzjB/Xr4ejKZLAcTQwPmd8O0q6bcV13KrvA3mdL4LpwjvzQufDPpsAlVTy+G104CvjhlAmh3m2ALvpPruvF+Ikf8BMjso1XkD7bANftlGawFE0MX6vSynLNuPRVXyuHvFSZI0PKJV5ihhSIGKLrFTrSdxugS3G1XHQVImobAXizDWCYqVKlaGK4fmwM14+pGVrJB2F8O/2kez//EEEjMg8LToMZGArnFhyuIf1kQyzjd9Ff3L3cRbdzCAzhWHwueVTMwjBxvMCl7QMh4yAI3J3cR8kVGcLRaegMB0IxFOlvYmSW+emXEd33/PmBP8AD/tBP+VciZUg/sAUaRv9F7gzDWTQ8ekcn3Ac//0NcduJyFQ4sMa7ivJPOzzdf3M6791IkR/GN+BpnYOgB87kdzKLed8uf/Ss2iNyPqY0PzfB/iWG4w58COwiBncFN/uhKJ4Q5xc5x31+FOPrejiaE6CHBD07et/plsHtCM5RHX8TEEDQ8i2+B4VVEwOOfN0fE0e79SdyAYfy1uIF64IEMwe/9adpWNByKYSXsBxfWhyaG64diKHY4N6b7ozfc2j/zSuwUyjd4gABudDQu6POVC9olBozNVXAJ8CWXswNf9tvJZ3ZB9/wGXb6MjhwOXMbvFKr3x8SJoxo4JsguGZtVRNyhe1MMD4F884wMXxNDT03nfw1Pv8EBXE74IdKuYCfdT8kFc3wfw0lPX5XeO2ii7CeP4MsuhxlK76P85jd0+BKuUThfvtuBFXL9GkJsxNU1oxYmyMj8FmDDiikLzZBcmiF4MENciLNK7jPkR7k+ACvsX9xn0P0jhoNlq7r6JD/4vFJCF3N4wvpBDJ9k4P+FLEISDocDrj4v1H1IAtMGuO+Ug5NhQB4U7Edi6vCS2iGqhVuJzgU+T+xPLYgqvY97MnusHFCib1gvaEFwFYUAv2duh9C89OZNnOg5kTiYVuWp6gou3b5M44NqaOLWt74yVxV0LQ2w3glx8V1iqDdCsAVRpScOIVZJ6A9+w1Pyc7hF0lVuh9C8FIer+1FyKnCZW9XpZ1dfFa5+SPBXbNgEaNi6Ija0vjJXBTRDzENyw6+oA0M4Y4bUgqjSQyZD6f1CLlCbWp9PexPYIokh6YqkmRa0pcDnSdpH05agKSkO3JwRpvHhVRW3ofWVuaqgGD4wNobrx8Zw/dgYrh8PTxAY4n3fDesFaajU3LBKbBquH5uG68em4fqxabh+bBquH5uG68em4fqxabh+bBquH5uG60eThg7ux+0a7yNvuCNqNfT3fNdayuCo7j1vWB6a2mErDI2/YRCaNTydhWhohZuGd0WthiCfhw8KbxouGrUaEqI4VdDfg9t/7UafhHxk78d/EmDRqNXQfwpl/uss5AMTnavHR9TPQIV5MESxB//VSQrjx9dzQdKTCB/bLEUuwjDUalgEahi9upzeuXxkXyUfJPQYUkbxZwLf0gOjyO1CAvE5LrQ8GQh8yBQ1IBddN0GuOJPHaxj2c5hK3L7Yfxkfv6KYUYzrNE5FhxlByXoNaXVIUKZQQ/SFUz4S0vjoWqqKikk5VBgGlq+/T6jMdSODc1xg+Xs1OQA/XnDxdQ5CSZGsIC/g8/MBfA+0NMMEZbBzlduEGS4iZL5LOyxHNj65V94Yo/h2cYR3PYaB0pDOoziRzu73wmN9PfBiMdIgph1i2OD4DWmIgTGmKyFF7TZhzGSjN8bXkEUk91oB5atcq0CDhj59g6QJufjYP6xcw5WhQUM1JObmpkXY8UnGDXOhnYb/9u+3km9gGxTik4abjjOhQUPdlzq1Q28xPqS5/rZYOiyWeRq/E8xhKjDhGFuroZos23ttsGyC/JSuLbIwGmIKyrkORPEB6OF004HZJqzocBqJE1CYUP5RX4PZJRYATkThCl/8muahuKZUV0FU5TZhxr+PV6th+ZwmwHVOklvj80cGbXzmBtXGDHJeHEQBC1st4XBJrhaC4E6vmRWf0pAvYjtEX3014zZhxgdkvq4d/olbot0Odz8keq8NUYxf4lNlZIFQmy5Q7LDK/wPqgBs20JoENsjsno0OT3suuADEfRlzFfcIxO1b5dZhRkeDhmAekdMQ1LP3vPkjgxLFVqVhsfdZMGo1bIsWGnJdUCcbRkWthhV9aQGttMmZ2dQcEbUatkUxfl2To1oBUKcbhqJBQ3wQA1C7wu+qIQIvbyqOBCjH2nZ4xW22oHLlyijGb9XMNg3HQa2GFWv8AsribxrOhloNTV86SMPK1CFh5dowBFCKdRr6ey967+Z3S3GH5uzVrw9zQKlKglDtaIi6oQWoeGsKEnRy0g0JRhTvXPVklFJCXagEBSqGUl7mamM6G8oAxVarYQlwv9Q51O+XFtDKxNYqe6FBw9K1xZUe7Mo0zzYatpFn07AXGjTsu7boi03EHqjVcMjawkY7dTYNe6BWQwQ+BIltsQ6tNGwlz6ZhDzRoyN9AxMci6zCiPJuI3dGgIc5fALONh5nmuqnZFk0atkKr+FQZ2lrSgYfm7EWAyqm6pE7n4i0L+poAPufTZW2RgtRpoQ+GUCE31ILKsrqY1MzUHg+vnvr2E5/2KGZKtjnepmAL1GuIEpZMSnHRWP9MVBu0i7WJ2IhaDXFWio9HWoAmCNfa73lXoGUb20RsQoOGCT0y2YRJi7lNl/uy0aAhD1ujPBNVRLtonAN10tfUQwPKpG5O0w4947ftTE2wrJgbDKBM7qYhItfIWgAyu8looVbDifvSHNqnAflRrg2EWg0B+MWBeTQkqJM6tA74YtCgob/3gtsF79zXYbQSbZcQq7jJqNGg4emcYIeaa4edn4lqj5YJ5fTb5AT6tX1pCa7fxeLQ7ZmotuiZ0gsXsUFDmtVYPSkq1/Qd0p7oKwbFGy0XawMQb2yH2bfuIQL9Jcpe9y3q0bdZU7w04og5Wj6AbNd2WMToJZYXpCV0BIrct0WvEUC1WsNRv3/YGUNSfUkS1mvYFtMVWG8tXlJDbNDwTn2pwWAlsBdRzodFg4YEe05TwOJLCZV8XC0bNLx3OxzeEFMMHzMWigYNy56JwucVoWFOs7YoAHI3WvLcHA2U7+rRoCG1Q3uvjbbYJlnjl4Dsj2TASmbKbM8J4NG5j/nzRQbmneyIaQsjo+CIeiKmzfdsABpd2yGqF0yz590Gm4Y2GjRk1L/5cm4Nx7P2IENig4aqHerJSwXmLYoRrQE15Voz6jXEBxNh/tnwiqG5NRzPHFC3oC6sCrUa0k8zwPJwlO+ujYrRLFoJzc9kBECmazXEX3gqXSRmMTPzCZvMVOlOiloNcTi8Xfh7pHWYnzaJSD2h8hgLKmGDNUgKWazRsCXuwjM1Oq75fGpK0UwZ5SReBCA/3TXE79HcbX1YxJSFihqW4u6sU1BeanKDe6Nv9/nxMEiCZJpnonqimIERc0SJ59shUx7RxjBQXqpz4+8T/ynM/7AUfw94rv3SXpi2VmkNtRXjuBMwL7UaoGKFOQ297mue+xb9ME+xsg2wheBzZZbPZwKZrbFX1pcWMGN+28GU6rRQFthaEXx1eoChrn1pEbPltj3mbAesIn6YophTQjZbZ660L7UwX3a7Yl4ps1iOhvRD3I1YrobEjqHO58KSNCT+6+tLi6jvbsbHYjRsh3VoOHNTJHNZkyXmx8kSJFKtIb4Xo+TH3mCuCquKRa8tSmFlc+JcL1tDuPAULnqN3wozt8vp0KAhjYYl4+F1xmeiJsOjiFirIaFw64nVW9Ced29wBVUn60UPDYtYbTGojLOWa2bRoGELrJZ9AasUskHDB1oftsMaRWzQkO5QNOKBNFyjig0avrh2CAC+yrUSNGjIe95NbfGxNNTAyosffLZgNGjIk9LlPV86F1BHhO3CSxxiAewxT3W5KPlthOAgp3pP1BJRIFfU8M78wXyPPPhP4ZKeiZoXJRretwTAeLWGFe82id67832HdAWgIrqjjLUaAkCqQOS3val77f/7Fo+IBbdDbImeI5JFff9wkViyhvgblsfv44Yd003DJWvYDpuGS9bwdIZW2Pgl0k3Du6JBQxgPrzvrt9WL2DS866SmQUMZxcKD1aA6q8CmIa8t8IhQnnOhScPSZ/VJ1G1tUYNZS6RBw7Jn9U9v3oKG2xq/DlCmvQqltj1VoUHD8mf1sR0+wDNR04G7VIX01LhKvFB1DZVKW2AiNRqUP6uPGr6YPe+e6KwEYYp2+BLvAa8ODRq2w6bhXdGgoXlKuHaVv2l4VzRqiM9hBMevanvTTcO7okFD2vQWty/2eilYik3Du6JJw1bYNLwrmjTk52kaHmzbNLwrGjSsfq5tWx8uBg0alu/TIF7uM1GLQ4OG1a+93PZLF4MGDWv2abb7FktBvYYoYYsvzWwa3hW1GuKMBt9z2QRqqxvGgyrXlmjQMIERsWxGk0dZ/M2v1K9t1C6A+HUaqnrR477F5lfq1zZqF0D8ujnNhhVg03D9GK5hdsNGwznwc1NZ4ILybG2dO7d0kcmgBwf423HKR/mVhcsnqWLlHj3QKWVnZib1TLY5w3kq7Jenwmd5uyqcRQUtWjwoExYP9CsrmS4YriFQMA/WpAjM4lHj+l1c2PBB4uf8vFcVWKbc+MT5MR+dAkRx/us85JmLyqf0BvIMOPKr7PYFZtimwiTyVPDMpkJx81S0xUxm2CvPg/1sGh0xXEOsRfm6xbDfxoCFY/shLP25ePHbcSl0QWSjszRchRRUrEyxKT/cL8ysczlcLhgiyL2jnMEW89kOkiIVPkupKItZHplMmLjsh6cZGp0xXMPsho3BtWRvADJc8INwVlwsWvXtOAMqbitJ7Zdy17Gy4piUMkWu/PKlxqnnqbAfHzX4LE/FhMtRAYvglQtImcinR37gNUDCMTTccGdsGq4fK9eQHhXBJ7acYn/O8PdeRLOIq/V1ZkT0KU8WoRdt2MZYMtbfDlk9ODriy1jc/kLDDcjGivGW759g3fD0V/Bh/yiGkLiNCOr/Lf6Jh7P1ivhQGuJLAjwZ7Fz4n/pjU8P3rSp/OMO2h5rpPX10c/BV4nE1ZCgNncPVezEaOji2FLqVitHCWsYBCm+ObvYoJtINZRrCp5rpK5nweQQWkPtS1g3GyOP3yk3n60RBw+PbX749hiAaTAaANRRKFHtQ8P4+CdDzMy4bCvAlFT9fZAf8B004IDgpJnj89/9gHB0CHZDse74Svf/X62Eq1gJoKFctHmlOQ9qAhiQAaMEOKHLUEJ+tYQ1yGtLFK7RfoyEFxBCoIQShgjQhMA6FoyvfvXfhCjg39IStYQ+suQo/BEbQcMOdsWm4ftgaBgf8L4PPYABzzDBFLvQH5G4WUj+aHhD/Jx1PfnCjT20/+C/VBeP3waWt50DNO+jUiqv8lCPjhwmkyelwziFKX2tFfoHn/5KZa9NljJdJT/mBywqHp+SvEXinXy+U9RTKsjrTyAVRyJgcEQUNBU2+Pz29gSUTKod774cqDR3vIwQzBwUoVkf8CIe8H0xgnvmCAvqBVyohn9pxwe/0zoUjhWWwM/o0mxz54cEKBwl9/CqTFfSjePlwZCObZfDDU7atcfWwZJiOgY6tTjUKHqVew1HSDvlec/Tqgoss2kwEyuDCm11wNX/TniinBwDd0Az4MaqcX/aC9qO7LlCz2YtPrbjkh4Ezd2iMX5oc+9EhLSg+3eNySCfH5YjxMumRH2XICoen7K8AC8wk75PJjTpnFDwAWZPjwdZww/pQ0g7hPwwDp7NHjxdwN1fRmaqRQB8IajiC/pEGoowfjzW641RjEMXVXRP5ZQMzOEDa4wJoXEoNKECQwlgFB5UlDQpgD1doz/JTSeXsqgyrMw07MURaIina+nVDQUMaD/muNwp3TaD9Vw+I1N+kBwK5kDj0Q7pnQj8ea9ISMdEyg1rqlxmYOECuKHlcyhggcJDsWKWGKUo2A2PGQNmzAhaqDoUYMPa19euEknZIH9hx4yioWkPFgEj9e3pgYJ5oiOOByPiRqOnYR34ULTOoUTgTWAMDZCIiaFzKGEBQEGsY4lNOUYP8CsMV2CuLa9mlDBfiFjwAmRIxaOvXDbaGG9aHTcP1Y9Nw/dg0XD82DdePTcP1gzXcsGpI+f9RkUazqqmjdAAAAABJRU5ErkJggg==" /></p><p>PAL=palbociclib; LET=letrozole; PCB=placebo.</p><p>&nbsp;</p><p>A series of prespecified subgroup PFS analyses was performed based on prognostic factors and baseline characteristics to investigate the internal consistency of treatment effect. A reduction in the risk of disease progression or death in favour of the palbociclib plus letrozole arm was observed in all individual patient subgroups defined by stratification factors and baseline characteristics in the primary and in the updated analysis.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Based on the 31-May-2017 data cutoff date, this reduction in risk continued to be observed in the following subgroups: (1) patients with either visceral metastases (HR of 0.62 [95% CI: 0.47, 0.81], median progression-free survival [mPFS] 19.3 months versus 12.3 months) or without visceral metastases (HR of 0.50 [95% CI: 0.37, 0.67], mPFS 35.9 months versus 17.0 months) and (2) patients with either bone only disease (HR of 0.41 [95% CI: 0.26, 0.63], mPFS 36.2 months versus 11.2 months) or without bone-only disease (HR of 0.62 [95% CI: 0.50, 0.78], mPFS 24.2 months versus 14.5 months). Similarly, a reduction in the risk of disease progression or death in the palbociclib plus letrozole arm was observed in 512 patients whose tumour tested positive for Rb protein expression by immunohistochemistry (IHC) (HR of 0.543 [95% CI: 0.433, 0.681], mPFS 27.4 months versus 13.7 months). For the 51 patients IHC negative for Rb expression, the difference between treatment arms was not statistically significant (HR of 0.868 [95% CI: 0.424, 1.777], mPFS 23.2 versus 18.5 months) for the palbociclib plus letrozole arm versus the placebo plus letrozole arm, respectively.</p><p>&nbsp;</p><p>Additional efficacy measures (OR and time to response [TTR]) assessed in the sub-groups of patients with or without visceral disease based on the 31-May-2017 updated cutoff date are displayed in Table 7.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p><strong>Table 7. Efficacy results in patients with visceral or non-visceral disease from PALOMA&ndash;2 study (intent-to-treat population; 31-May-2017 cutoff date)</strong></p></td></tr><tr><td>&nbsp;</td><td colspan="2"><p><strong>Visceral disease</strong></p></td><td colspan="2"><p><strong>Non-visceral disease</strong></p></td></tr><tr><td>&nbsp;</td><td><p><strong>Palbociclib plus letrozole</strong></p><p><strong>(N=214)</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>plus letrozole</strong></p><p><strong>(N=110)</strong></p></td><td><p><strong>Palbociclib plus letrozole</strong></p><p><strong>(N=230)</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>plus letrozole</strong></p><p><strong>(N=112)</strong></p></td></tr><tr><td><p>OR [% (95% CI)]</p></td><td><p>59.8</p><p>(52.9, 66.4)</p></td><td><p>46.4</p><p>(36.8, 56.1)</p></td><td><p>36.1</p><p>(29.9, 42.7)</p></td><td><p>31.3</p><p>(22.8, 40.7)</p></td></tr><tr><td><p>TTR, Median [months (range)]</p></td><td><p>5.4</p><p>(2.0, 30.4)</p></td><td><p>5.3</p><p>(2.6, 27.9)</p></td><td><p>3.0</p><p>(2.1, 27.8)</p></td><td><p>5.5</p><p>(2.6, 22.2)</p></td></tr><tr><td colspan="5"><p>N=number of patients; CI=confidence interval; OR=objective response based on confirmed and unconfirmed responses according to RECIST 1.1; TTR=time to first tumour response.</p></td></tr></tbody></table><p>&nbsp;</p><p>At the time of the updated analyses, the median time from randomisation to second subsequent therapy was 38.8 months in the palbociclib + letrozole arm and 28.8 months in the placebo + letrozole arm, HR 0.73 (95% CI: 0.58, 0.91).</p><p>&nbsp;</p><p><em>Randomised Phase 3 Study PALOMA-3: Palbociclib<strong> </strong>in combination with fulvestrant</em></p><p>The efficacy of palbociclib in combination with fulvestrant versus fulvestrant plus placebo was evaluated in an international, randomised, double-blind, parallel-group, multicentre study conducted in women with HR-positive, HER2-negative locally advanced breast cancer not amenable to resection or radiation therapy with curative intent or metastatic breast cancer, regardless of their menopausal status, whose disease progressed after prior endocrine therapy in the (neo)adjuvant or metastatic setting.</p><p>&nbsp;</p><p>A total of 521 pre/peri- and postmenopausal women who had progressed on or within 12 months from completion of adjuvant endocrine therapy or on or within 1 month from prior endocrine therapy for advanced disease, were randomised 2:1 to palbociclib plus fulvestrant or placebo plus fulvestrant and stratified by documented sensitivity to prior hormonal therapy, menopausal status at study entry (pre/peri- versus postmenopausal), and presence of visceral metastases. Pre/perimenopausal women received the LHRH agonist goserelin. Patients with advanced/metastatic, symptomatic, visceral spread, that were at risk of life-threatening complications in the short term (including patients with massive uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary lymphangitis, and over 50% liver involvement), were not eligible for enrolment into the study.</p><p>&nbsp;</p><p>Patients continued to receive assigned treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first. Crossover between treatment arms was not allowed.</p><p>&nbsp;</p><p>Patients were well matched for baseline demographics and prognostic characteristics between the palbociclib plus fulvestrant arm and the placebo plus fulvestrant arm. The median age of patients enrolled in this study was 57 years (range 29, 88). In each treatment arm the majority of patients were White, had documented sensitivity to prior hormonal therapy, and were postmenopausal. Approximately 20% of patients were pre/perimenopausal. All patients had received prior systemic therapy and most patients in each treatment arm had received a previous chemotherapy regimen for their primary diagnosis. More than half (62%) had an ECOG PS of 0, 60% had visceral metastases, and 60% had received more than 1 prior hormonal regimen for their primary diagnosis.</p><p>&nbsp;</p><p>The primary endpoint of the study was investigator-assessed PFS evaluated according to RECIST 1.1. Supportive PFS analyses were based on an Independent Central Radiology Review. Secondary endpoints included OR, CBR, overall survival (OS), safety, and time-to-deterioration (TTD) in pain endpoint.</p><p>&nbsp;</p><p>The study met its primary endpoint of prolonging investigator-assessed PFS at the interim analysis conducted on 82% of the planned PFS events; the results crossed the prespecified Haybittle-Peto efficacy boundary (&alpha;=0.00135), demonstrating a statistically significant prolongation in PFS and a clinically meaningful treatment effect. A more mature update of efficacy data is reported in Table 8.</p><p>&nbsp;</p><p>After a median follow-up time of 45 months, the final OS analysis was performed based on 310 events (60% of randomised patients). A 6.9-month difference in median OS in the palbociclib plus fulvestrant arm compared with the placebo plus fulvestrant arm was observed; this result was not statistically significant at the prespecified significance level of 0.0235 (1-sided). In the placebo plus fulvestrant arm, 15.5% of randomised patients received palbociclib and other CDK inhibitors as post progression subsequent treatments.</p><p>&nbsp;</p><p>The results from the investigator-assessed PFS and final OS data from PALOMA-3 study are presented in Table 8. The relevant Kaplan-Meier plots are shown in Figures 2 and 3, respectively.</p><p>&nbsp;</p><p><strong>Table 8. Efficacy results &ndash; PALOMA-3 study (investigator assessment, intent-to-treat population)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td><td colspan="2"><p><strong>Updated analysis</strong></p><p><strong>(23 October 2015 cutoff)</strong></p></td></tr><tr><td>&nbsp;</td><td><p><strong>Palbociclib plus fulvestrant</strong></p><p><strong>(N=347)</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>plus fulvestrant</strong></p><p><strong>(N=174)</strong></p></td></tr><tr><td><p><strong>Progression-free survival (PFS)</strong></p></td><td colspan="2">&nbsp;</td></tr><tr><td><p>Number of events (%)</p></td><td><p>200 (57.6)</p></td><td><p>133 (76.4)</p></td></tr><tr><td><p>Median [months (95% CI)]</p></td><td><p>11.2 (9.5, 12.9)</p></td><td><p>4.6 (3.5, 5.6)</p></td></tr><tr><td><p>Hazard ratio (95% CI) and p-value</p></td><td colspan="2"><p>0.497 (0.398, 0.620), p&lt; 0.000001</p></td></tr><tr><td colspan="2"><p><strong>Secondary efficacy endpoints</strong></p></td><td>&nbsp;</td></tr><tr><td><p>OR [% (95% CI)]</p></td><td><p>26.2 (21.7, 31.2)</p></td><td><p>13.8 (9.0, 19.8)</p></td></tr><tr><td><p>OR (measurable disease) [% (95% CI)]</p></td><td><p>33.7 (28.1, 39.7)</p></td><td><p>17.4 (11.5, 24.8)</p></td></tr><tr><td><p>CBR [% (95% CI)]</p></td><td><p>68.0 (62.8, 72.9)</p></td><td><p>39.7 (32.3, 47.3)</p></td></tr><tr><td colspan="3"><p><strong>Final overall survival (OS)</strong></p><p><strong>(13 April 2018 cutoff)</strong></p></td></tr><tr><td><p>Number of events (%)</p></td><td><p>201 (57.9)</p></td><td><p>109 (62.6)</p></td></tr><tr><td><p>Median [months (95% CI)]</p></td><td><p>34.9 (28.8, 40.0)</p></td><td><p>28.0 (23.6, 34.6)</p></td></tr><tr><td><p>Hazard ratio (95% CI) and p-value<sup>&dagger;</sup></p></td><td colspan="2"><p>0.814 (0.644, 1.029)</p><p>p=0.0429<sup>&dagger;*</sup></p></td></tr><tr><td colspan="3"><p>CBR=clinical benefit response; CI=confidence interval; N=number of patients; OR=objective response.</p><p>Secondary endpoint results are based on confirmed and unconfirmed responses according to RECIST 1.1.</p></td></tr></tbody></table><p><sup>*&nbsp;</sup>Not statistically significant.</p><p><sup>&dagger;&nbsp;</sup>1-sided p-value from the log-rank test stratified by the presence of visceral metastases and sensitivity to prior endocrine therapy per randomisation.</p><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;2. Kaplan-Meier plot of progression-free survival (investigator assessment, intent-to-treat population) &ndash; PALOMA-3</strong>&nbsp;<strong>study (23 October 2015 cutoff)</strong></p><p><img alt="" width="423" height="301" src="data:image/png;base64,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" /></p><p>FUL=fulvestrant; PAL=palbociclib; PCB=placebo.</p><p>&nbsp;</p><p>A reduction in the risk of disease progression or death in the palbociclib plus fulvestrant arm was observed in all individual patient subgroups defined by stratification factors and baseline characteristics. This was evident for pre/perimenopausal women (HR of 0.46 [95% CI: 0.28, 0.75]) and postmenopausal women (HR of 0.52 [95% CI: 0.40, 0.66]) and patients with visceral site of metastatic disease (HR of 0.50 [95% CI: 0.38, 0.65]) and non-visceral site of metastatic disease (HR of 0.48 [95% CI: 0.33, 0.71]). Benefit was also observed regardless of lines of prior therapy in the metastatic setting, whether 0 (HR of 0.59 [95% CI: 0.37, 0.93]), 1 (HR of 0.46 [95% CI: 0.32, 0.64]), 2 (HR of 0.48 [95% CI: 0.30, 0.76]), or &ge; 3 lines (HR of 0.59 [95% CI: 0.28, 1.22]).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure&nbsp;3. Kaplan-Meier plot of overall survival (intent-to-treat population) &ndash; PALOMA-3 study (13 April 2018 cutoff)</strong></p><p><img alt="" width="474" height="367" src="data:image/png;base64,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" /></p><p>FUL=fulvestrant; PAL=palbociclib; PCB=placebo.</p><p>&nbsp;</p><p>Additional efficacy measures (OR and TTR) assessed in the sub-groups of patients with or without visceral disease are displayed in Table 9.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p><strong>Table 9. Efficacy results in visceral and non-visceral disease from PALOMA&ndash;3 study</strong></p><p><strong>(intent-to-treat population)</strong></p></td></tr><tr><td>&nbsp;</td><td colspan="2"><p><strong>Visceral disease</strong></p></td><td colspan="2"><p><strong>Non-visceral disease</strong></p></td></tr><tr><td>&nbsp;</td><td><p><strong>Palbociclib plus fulvestrant</strong></p><p><strong>(N=206)</strong></p></td><td><p><strong>Placebo plus fulvestrant</strong></p><p><strong>(N=105)</strong></p></td><td><p><strong>Palbociclib plus fulvestrant</strong></p><p><strong>(N=141)</strong></p></td><td><p><strong>Placebo plus fulvestrant</strong></p><p><strong>(N=69)</strong></p></td></tr><tr><td><p>OR [%, (95% CI)]</p></td><td><p>35.0</p><p>(28.5, 41.9)</p></td><td><p>13.3</p><p>(7.5, 21.4)</p></td><td><p>13.5</p><p>(8.3, 20.2)</p></td><td><p>14.5</p><p>(7.2, 25.0)</p></td></tr><tr><td><p>TTR, Median [months (range)]</p></td><td><p>3.8</p><p>(3.5, 16.7)</p></td><td><p>5.4</p><p>(3.5, 16.7)</p></td><td><p>3.7</p><p>(1.9, 13.7)</p></td><td><p>3.6</p><p>(3.4, 3.7)</p></td></tr><tr><td colspan="5"><p>N=number of patients; CI=confidence interval; OR=objective response based on confirmed and unconfirmed responses according to RECIST 1.1; TTR=time to first tumour response.</p></td></tr></tbody></table><p>&nbsp;</p><p>Patient-reported symptoms were assessed using the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 and its Breast Cancer Module (EORTC QLQ-BR23). A total of 335 patients in the palbociclib plus fulvestrant arm and 166 patients in the fulvestrant only arm completed the questionnaire at baseline and at least 1 postbaseline visit.</p><p>&nbsp;</p><p>Time-to-Deterioration was prespecified as time between baseline and first occurrence of &ge; 10 points increase from baseline in pain symptom scores. Addition of palbociclib to fulvestrant resulted in a symptom benefit by significantly delaying time-to-deterioration in pain symptom compared with placebo plus fulvestrant (median 8.0 months versus 2.8 months; HR of 0.64 [95% CI: 0.49, 0.85]; p&lt; 0.001).</p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with palbociclib<strong> </strong>in all subsets of the paediatric population in the treatment of breast carcinoma (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of palbociclib were characterised in patients with solid tumours including advanced breast cancer and in healthy volunteers.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>The mean C<sub>max</sub>&nbsp;of palbociclib is generally observed between 6 to 12 hours following oral administration. The mean absolute bioavailability of palbociclib after an oral 125 mg dose is 46%. In the dosing range of 25 mg to 225 mg, the area under the curve (AUC) and C<sub>max</sub>&nbsp;increase proportionally with dose in general. Steady state was achieved within 8 days following repeated once daily dosing. With repeated once daily administration, palbociclib accumulates with a median accumulation ratio of 2.4 (range 1.5-4.2).</p><p>&nbsp;</p><p><u>Food effect</u></p><p>Palbociclib absorption and exposure were very low in approximately 13% of the population under the fasted condition. Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent. Compared to palbociclib given under overnight fasted conditions, the AUC<sub>inf</sub>&nbsp;and C<sub>max</sub>&nbsp;of palbociclib increased by 21% and 38% when given with high-fat food, by 12% and 27% when given with low-fat food, and by 13% and 24% when moderate-fat food was given 1 hour before and 2 hours after palbociclib dosing. In addition, food intake significantly reduced the intersubject and intrasubject variability of palbociclib exposure. Based on these results, palbociclib should be taken with food (see section 4.2).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Binding of palbociclib to human plasma proteins&nbsp;<em>in vitro</em>&nbsp;was ~85%, with no concentration dependence. The mean fraction unbound (f<sub>u</sub>) of palbociclib in human plasma&nbsp;<em>in vivo</em>&nbsp;increased incrementally with worsening hepatic function. There was no obvious trend in the mean palbociclib f<sub>u&nbsp;</sub>in human plasma&nbsp;<em>in vivo</em>&nbsp;with worsening renal function.&nbsp;<em>In vitro</em>, the uptake of palbociclib into human hepatocytes occurred mainly via passive diffusion. Palbociclib is not a substrate of OATP1B1 or OATP1B3.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><em>In vitro</em>&nbsp;and&nbsp;<em>in vivo</em>&nbsp;studies indicate that palbociclib undergoes extensive hepatic metabolism in humans. Following oral administration of a single 125 mg dose of [<sup>14</sup>C]palbociclib to humans, the major primary metabolic pathways for palbociclib involved oxidation and sulphonation, with acylation and glucuronidation contributing as minor pathways. Palbociclib was the major circulating drug-derived entity in plasma.</p><p>&nbsp;</p><p>The majority of the material was excreted as metabolites. In faeces, the sulfamic acid conjugate of palbociclib was the major drug-related component, accounting for 25.8% of the administered dose.&nbsp;<em>In vitro</em>&nbsp;studies with human hepatocytes, liver cytosolic and S9 fractions, and recombinant sulphotransferase (SULT) enzymes indicated that CYP3A and SULT2A1 are mainly involved in the metabolism of palbociclib.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The geometric mean apparent oral clearance (CL/F) of palbociclib was 63 L/h, and the mean plasma elimination half-life was 28.8 hours in patients with advanced breast cancer. In 6 healthy male subjects given a single oral dose of [<sup>14</sup>C]palbociclib, a median of 92% of the total administered radioactive dose was recovered in 15 days; faeces (74% of dose) was the major route of excretion, with 17% of the dose recovered in urine. Excretion of unchanged palbociclib in faeces and urine was 2% and 7% of the administered dose, respectively.</p><p>&nbsp;</p><p><em>In vitro</em>, palbociclib is not an inhibitor of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, and 2D6, and is not an inducer of CYP1A2, 2B6, 2C8, and 3A4 at clinically relevant concentrations.</p><p>&nbsp;</p><p><em>In vitro</em>&nbsp;evaluations indicate that palbociclib has low potential to inhibit the activities of organic anion transporter (OAT)1, OAT3, organic cation transporter (OCT)2, organic anion transporting polypeptide (OATP)1B1, OATP1B3, and bile salt export pump (BSEP) at clinically relevant concentrations.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Age, gender, and body weight</em></p><p>Based on a population pharmacokinetic analysis in 183 patients with cancer (50 male and 133 female patients, age ranging from 22 to 89 years, and body weight ranging from 38 to 123 kg), gender had no effect on the exposure of palbociclib, and age and body weight had no clinically important effect on the exposure of palbociclib.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Pharmacokinetics of palbociclib has not been evaluated in patients &lt; 18 years of age.</p><p><em>Hepatic impairment</em></p><p>Data from a pharmacokinetic trial in subjects with varying degrees of hepatic function indicate that palbociclib unbound exposure (unbound AUC<sub>inf</sub>) decreased by 17% in subjects with mild hepatic impairment (Child-Pugh class A), and increased by 34% and 77% in subjects with moderate (Child-Pugh class B) and severe (Child-Pugh class C) hepatic impairment, respectively, relative to subjects with normal hepatic function. Peak palbociclib unbound exposure (unbound C<sub>max</sub>) was increased by 7%, 38% and 72% for mild, moderate and severe hepatic impairment, respectively, relative to subjects with normal hepatic function. In addition, based on a population pharmacokinetic analysis that included 183 patients with advanced cancer, where 40 patients had mild hepatic impairment based on National Cancer Institute (NCI) classification (total bilirubin &le; Upper Limit of Normal (ULN) and Aspartate Aminotransferase (AST) &gt; ULN, or total bilirubin &gt; 1.0 to 1.5 &times; ULN and any AST), mild hepatic impairment had no effect on the pharmacokinetics of palbociclib.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Data from a pharmacokinetic trial in subjects with varying degrees of renal function indicate that total palbociclib exposure (AUC<sub>inf</sub>) increased by 39%, 42%, and 31% with mild (60 mL/min &le; CrCl &lt; 90 mL/min), moderate (30 mL/min &le; CrCl &lt; 60 mL/min), and severe (CrCl &lt; 30 mL/min) renal impairment, respectively, relative to subjects with normal (CrCl &ge; 90 mL/min) renal function. Peak palbociclib exposure (C<sub>max</sub>) was increased by 17%, 12%, and 15% for mild, moderate, and severe renal impairment, respectively, relative to subjects with normal renal function. In addition, based on a population pharmacokinetic analysis that included 183 patients with advanced cancer, where 73 patients had mild renal impairment and 29 patients had moderate renal impairment, mild and moderate renal impairment had no effect on the pharmacokinetics of palbociclib. The pharmacokinetics of palbociclib have not been studied in patients requiring haemodialysis.</p><p>&nbsp;</p><p><em>Ethnicity</em></p><p>In a pharmacokinetic study in healthy volunteers, palbociclib AUC<sub>inf</sub>&nbsp;and C<sub>max</sub>&nbsp;values were 30% and 35% higher, respectively, in Japanese subjects compared with non-Asian subjects after a single oral dose. However, this finding was not reproduced consistently in subsequent studies in Japanese or Asian breast cancer patients after multiple dosing. Based on an analysis of the cumulative pharmacokinetic, safety, and efficacy data across Asian and non-Asian populations, no dose adjustment based on Asian race is considered necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The primary target organ findings of potential relevance to humans included haematolymphopoietic and male reproductive organ effects in rats and dogs in studies up to 39 weeks duration. Effects on glucose metabolism were associated with findings in the pancreas and secondary effects on eye, teeth, kidney, and adipose tissue in studies &ge; 15 weeks duration in rats only and bone changes were observed in rats only following 27 weeks of dosing. These systemic toxicities were generally observed at clinically relevant exposures based on AUC. In addition, cardiovascular effects (QTc prolongation, decreased heart rate, and increased RR interval and systolic blood pressure) were identified in telemetered dogs at &ge; 4 times human clinical exposure based on C<sub>max</sub>. The reversibility of the effects on glucose homeostasis, pancreas, eye, kidney, and bone was not established following a 12-week nondosing period, whereas partial to full reversal of effects on the haematolymphopoietic and male reproductive systems, teeth, and adipose tissue was observed.</p><p>&nbsp;</p><p><u>Carcinogenicity</u></p><p>Palbociclib was assessed for carcinogenicity in a 6-month transgenic mouse study and in a 2-year rat study. Palbociclib was negative for carcinogenicity in transgenic mice at doses up to 60 mg/kg/day (No Observed Effect Level [NOEL] approximately 11 times human clinical exposure based on AUC). Palbociclib-related neoplastic finding in rats included an increased incidence of microglial cell tumours in the central nervous system of males at 30 mg/kg/day; there were no neoplastic findings in female rats at any dose up to 200 mg/kg/day. The NOEL for palbociclib-related carcinogenicity effects was 10 mg/kg/day (approximately 2 times the human clinical exposure based on AUC) and 200 mg/kg/day (approximately 4 times the human clinical exposure based on AUC) in males and females, respectively. The relevance of the male rat neoplastic finding to humans is unknown.</p><p>&nbsp;</p><p><u>Genotoxicity</u></p><p>Palbociclib was not mutagenic in a bacterial reverse mutation (Ames) assay and did not induce structural chromosomal aberrations in the&nbsp;<em>in vitro</em>&nbsp;human lymphocyte chromosome aberration assay.</p><p>&nbsp;</p><p>Palbociclib induced micronuclei via an aneugenic mechanism in Chinese Hamster Ovary cells&nbsp;<em>in vitro</em>&nbsp;and in the bone marrow of male rats at doses &ge; 100 mg/kg/day. The exposure of animals at the no observed effect level for aneugenicity was approximately 7 times human clinical exposure based on AUC.</p><p>&nbsp;</p><p><u>Impairment of fertility</u></p><p>Palbociclib did not affect mating or fertility in female rats at any dose tested up to 300 mg/kg/day (approximately 3 times human clinical exposure based on AUC), and no adverse effects were observed in female reproductive tissues in repeat-dose toxicity studies up to 300 mg/kg/day in the rat and 3 mg/kg/day in the dog (approximately 5 and 3 times human clinical exposure based on AUC, respectively).</p><p>&nbsp;</p><p>Palbociclib is considered to have the potential to impair reproductive function and fertility in male humans based on non-clinical findings in rats and dogs. Palbociclib-related findings in the testis, epididymis, prostate, and seminal vesicle included decreased organ weight, atrophy or degeneration, hypospermia, intratubular cellular debris, lower sperm motility and density, and decreased secretion. These findings were observed in rats and/or dogs at exposures &ge; 9 times or subtherapeutic compared to human clinical exposure based on AUC, respectively. Partial reversibility of male reproductive organ effects was observed in the rat and dog following a 4- and 12-week nondosing period, respectively. Despite these male reproductive organ findings, there were no effects on mating or fertility in male rats at projected exposure levels 13 times human clinical exposure based on AUC.</p><p>&nbsp;</p><p><u>Developmental toxicity</u></p><p>Palbociclib is a reversible inhibitor of cyclin-dependent kinases 4 and 6, which are both involved in regulating the cell cycle. It may therefore have risk of foetal harm if used during pregnancy. Palbociclib was foetotoxic in pregnant animals. An increased incidence of a skeletal variation (increased incidence of a rib present at the seventh cervical vertebra) at &ge; 100 mg/kg/day was observed in rats. Reduced foetal body weights were observed at a maternally toxic dose of 300 mg/kg/day in rats (3 times human clinical exposure based on AUC), and an increased incidence of skeletal variations, including small phalanges in the forelimb was observed at a maternally toxic dose of 20 mg/kg/day in rabbits (4 times human clinical exposure based on AUC). Actual foetal exposure and cross-placenta transfer have not been examined.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp; Microcrystalline cellulose</p><p>-&nbsp; Lactose</p><p>-&nbsp; Sodium starch glycolate</p><p>-&nbsp; Aerosil</p><p>-&nbsp; Magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p>Store in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum/aluminum blisters.</p><p>&nbsp;</p><p>Pack size: 21 hard capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: jpimedical@hikma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02 September 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>